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Abstract 
Tuberculosis, caused primarily by the bacillus Mycobacterium tuberculosis (Mtb), is the 
leading cause of bacterial infectious disease mortality. Mtb scavenges the essential 
micronutrient iron from its host via the synthesis, secretion, and reuptake of small-
molecule iron chelators known as siderophores. Siderophores in Mtb, termed 
mycobactins, have been linked to virulence through targeted genetic disruption of the 
mycobactin biosynthetic pathway, validating inhibition of mycobactin biosynthesis for 
the development of novel antitubercular agents. Mycobactins are synthesized by mixed 
nonribosomal peptide synthetiase/polyketide synthase (NRPS/PKS) machinery in Mtb. 
The NRPS assembly line is primed by an aryl acid adenylating enzyme (AAAE) from 
Mtb known as MbtA. MbtA is an attractive therapeutic target due to lack of a human 
homologue, availability of structural information from homologous AAAEs, and 
extensive knowledge of the enzymatic mechanism of a functionally- and structurally-
similar AAAE. The MbtA mechanism and a potent MbtA bisubstrate inhibitor, 5′-O-[N-
(salicyl)sulfamoyl]adenosine (Sal-AMS), are shown in the figure below. While 
demonstrating some adequate pharmacokinetic parameters, Sal-AMS is ultimately 
plagued by poor oral bioavailability. Previous studies in our lab indicate that an internal 
hydrogen bond is formed between the phenol and charged sulfamate nitrogen atom 
(estimated pKa around 2) of Sal-AMS, enforcing a coplanar arrangement of the salicyl 
group when bound to the MbtA active site. We thus proposed the synthesis of 
conformationally constrained analogues 1–3 to mimic the bound conformation of Sal-
AMS and potentially improve the oral bioavailability of the parent Sal-AMS compound 
by removing two rotatable bonds and the charged sulfamate moiety. Oral bioavailability 
studies are dependent on the proposed analogues’ relative biochemical and antitubercular 
potencies versus those of Sal-AMS. Herein is reported the synthesis, biochemical and 
antitubercular evaluation of conformationally constrained analogues of Sal-AMS 1–3, as 
well as its 2,3-dihydroxybenzoyl variant 4. 
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 1 
Introduction 
Tuberculosis (TB) is caused primarily by the bacillus Mycobacterium tuberculosis 
(Mtb) and is the leading cause of bacterial infectious disease mortality, responsible for 
about 1.4 million worldwide deaths in 2011.1,2 It is estimated that one-third of the world’s 
population has latent TB and 8.7 million new infections occurred in 2011.1 Current 
treatment of TB, known as Directly Observed Treatment Short-course, requires six to 
nine months of combination chemotherapy.3 The emergence of multidrug resistant and 
extensively drug resistant TB strains and a lack of approval of any new antitubercular 
(anti-TB) agent in over four decades underscore the urgency of drug development for this 
worldwide clinical need.3 
Iron is an essential micronutrient for almost all known organisms. However iron is 
extremely insoluble in biological fluids and the concentration of free iron is further 
repressed in a mammalian host by lactoferrin and transferrin to an astonishing 10-24 M, 
which is far too low to support bacterial colonization and growth.4 Many pathogenic 
bacteria obtain iron via the synthesis, secretion, and reuptake of small-molecule iron 
chelators known as siderophores (Figure 1).4 Siderophores in Mtb, termed mycobactins, 
have been linked to virulence through targeted genetic disruption of the mycobactin 
biosynthetic pathway, validating inhibition of mycobactin biosynthesis for the 
development of novel anti-TB agents.5 
 2 
 
Figure 1. Representative aryl-capped siderophores, with iron-chelating regions highlighted in red. 
 
Mycobactins are biosynthesized by a mixed nonribosomal peptide 
synthetase/polyketide synthase (NRPS/PKS) pathway in Mtb (Figure 2).6 The NRPS 
assembly line is primed by an aryl acid adenylating enzyme (AAAE) from Mtb known as 
MbtA.6 MbtA catalyzes a two-step adenylation/acylation reaction. In the adenylation 
half-reaction, salicylate and ATP are bound and condensed, releasing pyrophosphate but 
keeping the acyladenylate intermediate tightly bound. MbtA then binds the downstream 
aryl carrier protein (ArCP) domain of MbtB and transfers the aryl acid moiety onto the 
terminal thiol of the phosphopantetheinyl cofactor arm of the ArCP domain, thereby 
priming the NRPS assembly line for mycobactin biosynthesis. MbtA is an attractive 
therapeutic target7 due to lack of a human homologue, availability of high-resolution co-
crystal structures of related AAAEs with bound acyladenylate intermediate8 and 
bisubstrate inhibitor,9 and knowledge of the enzymatic mechanism of structurally- and 
functionally-similar EntE that has been extensively studied (EntE bears 40% amino acid 
 3 
identity to MbtA and adenylates 2,3-dihydroxybenzoic acid [DHBA] versus salicylic acid 
[SAL]).10 MbtA is also a member of the highly studied superfamily of adenylate-forming 
enzymes11 for which inhibitors have already been developed and are in clinical use.12 The 
MbtA mechanism and a prototypical AAAE bisubstrate inhibitor, 5′-O-[N-
(salicyl)sulfamoyl]adenosine (Sal-AMS), are shown in Figure 3 below.13,14 Sal-AMS is a 
rationally designed nucleoside inhibitor of MbtA whereby the hydrolytically labile 
acylphosphate moiety of the tightly-bound intermediate is replaced by a stabile 
acylsulfamate linker, inspired by the natural product ascamycin, an alanyladenylate 
mimic isolated from an unknown Streptomyces species in Japan.15  
 
Figure 2. Mycobactin biosynthetic initiation and elongation. 
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Figure 3. A. Enzymatic reactions catalyzed by MbtA, with hydrolytically labile acylphosphate outlined in 
blue. B. Sal-AMS and natural product ascamycin, from which Sal-AMS draws its inspiration for the 
hydrolytically stabile acylsulfamate bioisostere, outlined in blue. 
 
Sal-AMS is a tight-binding inhibitor of MbtA with an equilibrium dissociation 
constant (KD) value on the order of 1 pM and an apparent equilibrium dissociation 
constant of the enzyme–inhibitor complex (Kiapp) of 6.6 nM.16 Furthermore, Sal-AMS 
displays potent whole cell activity against Mtb clinical isolate H37Rv under relevant iron-
limiting conditions, with a minimum inhibitory concentration that inhibits >99% cell 
growth (MIC99) of 0.39 µM, rivaling the first-line clinical agent isoniazid.14,16 To date, 
our laboratory has conducted extensive structure–activity relationship (SAR) studies on 
Sal-AMS, systematically exploring its aryl,16 linker,14,17 glycosyl,18 and nucleobase 
domains.19,20 These SAR findings, in conjunction with a quantum mechanical study in 
which Sal-AMS was docked in the binding site of an MbtA homology model,21 indicate 
that an internal hydrogen bond is formed between the phenol and sulfamate nitrogen 
atom (estimated pKa around 2) of Sal-AMS. This enforces a coplanar arrangement of the 
salicyl group when bound to the MbtA active site. Further evidence in support of this 
 5 
notion is observed in the co-crystal structures of related AAAEs from Bacillus subtilis 
(DhbE) and Acinetobacter baumannii (BasE) (Figure 4). 
 
Figure 4. A (Left; center; right). Molecular structure of DHB-AMP; co-crystal structure of enzymatic 
intermediate DHB-AMP bound to AAAE DhbE from B. subtilis (PDB ID: 1MDB) with aryl ring in plane 
of paper; same co-crystal structure, rotated 90°, with aryl ring perpendicular to paper. B (Left; center; 
right). Molecular structure of DHB-AMS; co-crystal structure of bisubstrate mimic DHB-AMS bound to 
AAAE BasE from A. baumannii. (PDB ID: 3O82), with aryl ring in plane of paper; same co-crystal 
structure, rotated 90°, with aryl ring perpendicular to paper. 
 
Preliminary pharmacokinetic (PK) parameters of Sal-AMS were obtained using 
deuterium-labeled Sal-AMS as internal standard in a tandem liquid chromatography–
mass spectrometry method to measure plasma concentrations.22 Initial studies with 300 
mg/kg administration by oral gavage afforded Cmax, tmax, t1/2, and CLapp values of 28.2 ± 
1.9 µM, 30 min, 1.97 ± 0.62 h, and 16.2 mL/min•kg respectively. The findings 
demonstrate that Sal-AMS possesses some adequate PK parameters (for example, the 
Cmax is about 72-fold higher than the MIC99 value) but is ultimately plagued by poor oral 
bioavailability.23 We have proposed a number of structural modifications to Sal-AMS to 
improve its oral bioavailability; one set of modifications is the subject of this master’s 
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thesis. Based on the aforementioned SAR, quantum mechanical, and co-crystal studies, 
we proposed the synthesis of conformationally constrained analogues 1–3, shown below 
in Figure 5. The proposed analogues mimic the hypothesized MbtA-bound conformation 
of Sal-AMS, removing two rotatable bonds and the charged sulfamate moiety. We expect 
these changes to improve the oral bioavailability of the parent Sal-AMS compound, 
studies depending on the proposed analogues’ relative biochemical and antitubercular 
potencies versus those of Sal-AMS. Herein is reported the synthesis, biochemical and 
antitubercular evaluation of conformationally constrained analogues of Sal-AMS 1–3, as 
well as its DHB variant 4. 
 
Figure 5. Conformationally constrained analogues of Sal-AMS 1–3, and conformationally constrained 
analogue of DHB-AMS 4. 
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Results and Discussion 
Synthesis. 
The most concise synthesis we envisioned toward the proposed bicyclic-AMS 
analogues involves disconnection of 1–4 by Mitsunobu reaction to bicyclic sulfonamides, 
inspired by our previous work on β-ketosulfonamide-based Sal-AMS analogues (Figure 
6).17 Further retrosynthesis leads to acetophenone or benzoic acid derivatives. 
 
Figure 6. Retrosynthetic analysis. 
  
Our original route to chromone-AMS 1 proposed five steps from β-ketosulfonamide 5 
(Figure 7), prepared according to our published method.17 Trifluoroacetic acid (TFA) 
deprotection followed by one-carbon homologation with N,N-dimethylformamide 
dimethyl acetal (DMF-DMA) and cyclization under acidic conditions (for example, para-
toluenesulfonic acid [TsOH]) was anticipated to afford chromone-3-sulfonamide 7.24,25 
Necessary26,27 tert-butylcarbamate (Boc) protection of the sulfonamide28 to give 8 
followed by Mitsunobu coupling17 with appropriately protected adenosine 929 would 
afford penultimate protected chromone-AMS 10. Global deprotection under 80% aqueous 
(aq) TFA conditions would provide chromone-AMS 1. 
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Figure 7. Initially proposed route to chromone-AMS 1. 
 
A review of the literature before initiating synthetic efforts suggested a potentially 
shorter route to 1. It was found that isolable intermediate enaminone 12 from the 1971 
synthesis of chromone 13 (Figure 8A)24 was successfully used in a tandem 
sulfamoylation–cyclization with chlorosulfonylureas to produce chromone-3-
sulfonylureas in 1996 (Figure 8B).30 Based on our lab’s experience with the 
sulfamoylating reagent sulfamoyl chloride 14,14,16,18,19,31 it seemed entirely feasible to 
arrive at intermediate chromone-3-sulfonamide 7 (Figure 8C) in short order from known 
enaminone 12,24 itself derived from commercial starting materials in one step (versus 
three steps to β-ketosulfonamide 6). 
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Figure 8. A. 1971 route to chromone 13. B. 1996 route to chromone-3-sulfonylureas. C. Proposed 
shortened route to chromone-3-sulfonamide 7. 
 
Initial efforts to synthesize chromone-3-sulfonamide 7 through tandem 
sulfamoylation–cyclization with enaminone 12 and sulfamoyl chloride 14 proved 
nontrivial. After several small-scale attempts and purifying 14 through recrystallization,32 
the highest isolated yield of desired 7 was a mere 5%. Thin-layer chromatography (TLC) 
monitoring of the reaction displayed a high degree of streaking, even upon dilution of the 
reaction mixture before spotting. This was indicative of the formation of multiple 
undesired side products. The other isolable and characterizable reaction products were 
chromone 13 (32%) and starting enaminone 12 (15% recovered). A majority of the 
remaining mass was a highly insoluble material that could not be characterized. Its 
identity was hypothesized to be that of polymerized desired product: upon concentration 
of a sample of crystalline 7 prepared for proton nuclear magnetic resonance spectroscopy 
(NMR), an insoluble solid similar in appearance to that isolated from the reaction 
developed. 
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Attention was turned toward the reactivity and thus instability of reagent 14 itself by 
these preliminary results. Another literature search was conducted to find similar, but less 
reactive sulfamoylating reagents. Two were found, both 4-(dimethylamino)pyridine 
(DMAP) stabilized but each differentially protected on their sulfonamide moieties 
(Figure 9). Each could be synthesized in one pot like sulfamoyl chloride, but they offered 
a couple of advantages over the analogous use of that reagent: 1) the sulfonamide 
functionality was already protected, and 2) each was stable for prolonged periods at room 
temperature under normal atmosphere. In short order, sulfamoylating reagents 1533 and 
1634 were prepared in ample amounts from their respective literature reports. 
 
Figure 9. Synthesis of sulfamoylating reagents 15 and 16. 
 
With the new sulfamoylating reagents in hand, conditions were screened to see 
whether they could participate in the desired tandem sulfamoylation–cyclization reaction. 
Unfortunately, even with heating, the reagents proved unable to effect the transformation 
(Table 1). Instead, enaminone 12 cyclized to chromone 13 under acid-free conditions at 
high temperature as monitored by TLC and low-resolution mass spectrometry (LRMS) 
and compared to authentic commercially obtained 13. The outcome suggested the 
reagents were far too bulky to give the desired outcome. Indeed, their described use is for 
the sulfamoylation of primary amines and hydroxyls. 
 
 11 
 
Temp. (°C) Time (h) Reaction? 
22 8 No 
40 16 No 
80a 24 Yes 
aDCM exchanged for 1,4-dioxane 
 
Table 1. Synthetic efforts to arrive at protected chromone-3-sulfonamides via sulfamoylating agents 15 and 
16. 
 
A look back at the work of Löwe and Matzanke30 suggested a hybrid approach of the 
first two failed routes to obtain the desired protected chromone-3-sulfonamide. They had 
utilized chlorosulfonylureas generated in situ for their tandem sulfamoylation–
cyclization. The chlorosulfonylureas themselves were derived from reaction of an 
appropriate amine with chlorosulfonyl isocyanate, strikingly reminiscent of the route to 
agents 15 and 16. Would it be possible to generate and use a carbamate-protected 
sulfamoyl chloride reagent in the same manner? 
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Figure 10. Löwe and Matzanke’s tandem reaction (upper) and the potential route it inspired (lower). 
 
tert-Butyl alcohol (t-BuOH) was chosen as it would yield a Boc-protected 
sulfonamide, presumably easily removed from the penultimate compound under the 
global deprotection conditions. Boc-protected sulfamoyl chloride 17 was generated in 
situ by addition of chlorosulfonyl isocyanate to a stirring solution of t-BuOH in 
dichloromethane (DCM). To this was added a stoichiometric equivalent of enaminone 12. 
Initial attempts proved promising as the desired mass-to-charge ratio (m/z) was observed 
in LRMS analysis, although purification appeared daunting as the reaction was initially 
as messy as that with unprotected sulfamoyl chloride when monitored by TLC. An 
unusual solvent system of hexanes and DCM proved invaluable to purify and isolate the 
desired Boc-protected chromone-3-sulfonamide 8 in an astonishingly low yield of 3%. 
Having that 3% however was more than enough to identify and isolate product from 
improved reaction conditions. 
As was the case with the use of sulfamoyl chloride, conditions improved with the use 
of recrystallized reagent. Although it added time to the synthetic scheme, and removed 
the in situ ease of reagent generation, recrystallizing 17 paid off with a seven-fold 
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increase in yield of 8. An optimized but still quite modest 21% yield was primarily the 
result of competitive cyclization of the enaminone 12 to chromone 13 under the acidic 
conditions afforded by release of hydrogen chloride (HCl) during reaction. It was 
hypothesized that changing the order and time length of addition of reagents could 
improve this yield even further, however that approach was not pursued. The facile 
nature of Mitsunobu coupling between nucleophile 8 and appropriately protected 
adenosine 9 rendered the low yield of 8 virtually inconsequential. Resultant penultimate, 
fully protected 10 underwent global deprotection facilitated by aqueous TFA to yield 
chromone-AMS 1 in just three linear steps from known enaminone 12. 
 
Figure 11. Final optimized scheme for the synthesis of 1 via key tandem sulfamoylation–cyclization.a 
aReaction Conditions: (a) t-BuOH, DCM, 0 to 22 °C, 83%; (b) DCM, 22 °C, 13 h, 21%; (c) PPh3, DIAD, 
THF, 0 to 22 °C, 6 h, 80%; (d) 80% aq TFA, 0 to 22 °C, 4 h, 76%; (e) (i) TBSCl, imidazole, DMF, 0 °C, 2 
h then 0 to 22 °C, 15 min, (ii) Boc2O, DMAP, Et3N, DMF, 0 to 22 °C, 87% over two steps, (iii) TBAF, 
THF, 22 °C, 1.5 h, 84%. 
 
Attention was then focused on the synthesis of quinolone-AMS 2. Initially, a route 
analogous to that of 1 was envisioned, whereby 2-aminoacetophenone 21 would be 
reacted with DMF-DMA to give the desired enaminone. However, a thorough inspection 
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of the structure as well as a literature search halted execution of those plans but did 
suggest a possible route.35 A protecting group strategy could potentially be used to 
attenuate the nucleophilicity of the aniline nitrogen, thereby allowing the desired 
transformation to be affected. Knowing that refluxing conditions were likely necessary to 
provide the enaminone, heat-stabile Cbz was chosen. The aniline nitrogen was Cbz-
protected under mildly basic conditions to afford carbamate 22 in quantitative yield 
(Figure 12A).36 Reaction with DMF diethyl acetal under refluxing conditions provided 
enaminone 23 in 45% yield.35 Attempts to affect tandem sulfamoylation–cyclization with 
Boc-sulfamoyl chloride 17 proved fruitless, unfortunately. Unlike with analogous 
hydroxy-enaminone 12, no trace of desired product 24 was ever detected. The reaction 
would not proceed as monitored by TLC, likely due to reduced aniline nucleophilicity 
following Cbz protection. Nearly quantitative recovery of the starting enaminone 23 was 
the result of every attempt. 
 
Figure 12. Attempted tandem sulfamoylation–cyclization via enaminone 23. 
 
Indeed, Löwe and Kietzmann were unable to affect reaction of tosylamino-enaminone 25 
with thionyl bromide (SOBr2) to sulfinic acid 26 (Figure 13A),35 analogous to the 
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reported conversion of hydroxy-enaminone 12 to sulfinic acid 27  via thionyl chloride 
(SOCl2) (Figure 13B).37 
 
Figure 13. A. Reported unsuccessful sulfination of tosylamine-enaminone 25.35 B. Reported sulfination of 
hydroxy-enaminone 12.37 
 
Briefly, the route originally proposed to achieve chromone-3-sulfonamide 8 (Figure 7) 
was considered to afford an appropriately protected quinolone-3-sulfonamide (Figure 14). 
The largest problem with this idea was the arrival at the β-ketosulfonamide without an 
extensive and exhaustive protecting group strategy. It was thus necessary to consult the 
literature. 
 
Figure 14. Retrosynthetic disconnections of quinolone-3-sulfonamide leading to a β-ketosulfonamide 
synthon. 
 
Structural similarity searches pointed toward the quinolone antibacterial agents,38 
specifically toward quinolone-3-carboxylic acids synthesized from β-ketoesters.39 A 
representative scheme is shown below in Figure 15. 2,4-Dichloro-5-fluoroacetophenone 
28 was condensed with diethyl carbonate under basic conditions to afford β-ketoester 29. 
Reaction with triethyl orthoformate in acetic anhydride afforded one-carbon 
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homologation product 30. Evaporation to dryness and exposure to slight excess of 4-
fluoroaniline resulted in addition–elimination product enaminone 31. Cyclization to 
quinolone ester 32 was realized through nucleophilic aromatic substitution under basic 
conditions with heating in dimethoxyethane. Saponification of ester 32 followed by 
modifications to carboxylic acid 33 yielded a series of 7-substituted quinolones. 
 
Figure 15. 1985 synthesis of arylfluoroquinolone-3-carboxylic acids from β-ketoesters. 
 
Acid 33 bore a striking resemblance to the desired quinolone-3-sulfonamide. The 
necessary β-ketosulfonamide 34, analogous to β-ketoester 29, could be realized through a 
novel Claisen-like condensation developed by our lab.17 A modified retrosynthetic 
scheme is shown below in Figure 16. 
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Figure 16. Revised retrosynthetic disconnections of quinolone-3-sulfonamide leading to an ortho-fluoro β-
ketosulfonamide synthon. 
 
Synthesis of the desired quinolone-3-sulfonamide commenced with esterification of 2-
fluorobenzoic acid under classic Fischer conditions in methanol with catalytic sulfuric 
acid to afford methyl ester 35. β-ketosulfonamide 34 was realized through the 
aforementioned Claisen-like condensation17 of the lithium diisopropylamide (LDA)-
generated dianion of N-Boc-methanesulfonamide 3628 with ester 35.  
 
Figure 17. Synthesis of β-ketosulfonamide 34. 
 
Reaction of β-ketosulfonamide 34 with triethyl orthoformate in acetic anhydride was 
attempted according to conditions outlined above,39 albeit at lower temperatures given the 
thermal lability of Boc protecting groups. Steadily increased heating resulted in reaction 
progression as monitored by TLC (Table 2). However, purification and characterization 
by LRMS and 1H NMR showed not only the desired homologation but also simultaneous 
Boc deprotection and Schiff base formation at the sulfonamide (Figure 18). 
 18 
 
 
Temp. (°C) Time (h) Reaction? 
22 0.5 No 
77 1.5 No 
90 7 Yes 
 
Table 2. Synthetic efforts to arrive at enol ether 37 through formylation with triethyl orthoformate. 
 
 
Figure 18. Outcome of reaction of β-ketosulfonamide 34 with triethyl orthoformate. 
 
An alternate protecting group strategy was considered whereby thermally stabile Cbz 
could be used instead of Boc. However, a recollection of Reiter’s mild conditions for 
homologation (introduced in Figure 7 above)25 focused attention on that strategy. 
Reaction of β-ketosulfonamide 34 with DMF-DMA resulted in full conversion as 
monitored by TLC to enaminone 39, as verified by LRMS and 1H NMR of the crude 
material after evaporation to dryness (Figure 19).25 Crude 39 was taken up in DCM and 
reacted with excess para-methoxybenzylamine (PMBNH2) to give an inconsequential 
mixture of transamination product E- and Z-PMB-enaminone 40,39 an exciting find 
because it meant the desired protecting group strategy could be retained. Under basic 
conditions with sodium hydride (NaH), cyclization of 40 via nucleophilic aromatic 
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substitution provided PMB-quinolone sulfonamide 41.39 Unfortunately, deprotection of 
the PMB under standard oxidative cleavage conditions with 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ)40 could not be achieved. Harsh conditions in neat TFA41 
afforded quinolone sulfonamide 42. Bis-Boc protection of 4242,43 followed by Mitsunobu 
coupling with adenosine 9 unexpectedly yielded a tris-Boc (rather than tetrakis-Boc) 
product 44. This underwent global deprotection facilitated by aqueous TFA to arrive at 
quinolone-AMS 2. 
 
Figure 19. Scheme for the synthesis of 2 via key nucleophilic aromatic substitution.a 
aReaction Conditions: (a) THF, 22 °C, 17 h; (b) DCM, 22 °C, 5 min, 81% over two steps; (c) NaH, 1,2-
DME, 0 to 22 °C, 19.5 h, 81%; (d) TFA, sealed tube, 72 °C, 17 h then 100 °C, 23 h, 58%; (e) Boc2O, 
DMAP, Et3N, DCM, 0 to 22 °C, 15 h, 18%; (f) PPh3, DIAD, THF, 0 to 22 °C, 17.5 h; (g) 80% aq TFA, 0 
°C, 24 h, 66% over two steps. 
 
The bis-deprotection followed by bis-reprotection was less than desirable because it 
added steps to the sequence and inherently caused major hits to the overall yield of 2. An 
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alternate protecting group strategy was investigated whereby the Boc-protected 
sulfonamide could be retained (Figure 20). Benzyl-quinolone sulfonamide 45 was 
realized in three steps from 34 without isolation of the intermediates. Reductive 
debenzylation with stoichiometric palladium on carbon44,45 afforded mono-deprotected 
quinolone sulfonamide 46. Efforts to protect quinolone 46 as its MOM amine46 proved 
quite difficult; potential product 47 was not isolated and conclusively verified despite 
multiple synthetic attempts. The facile nature of quinolone debenzylation of 45 in 
conjunction with our lab’s observed stability of adenosine derivatives to hydrogenation 
conditions inspired an alternate strategy. The benzyl protecting group of 45 was retained 
and successful Mitsunobu coupling with adenosine 9 afforded fully protected quinolone-
AMS 50. Debenzylation under standard conditions yielded protected 51, itself 
deprotected under acidic conditions to afford quinolone-AMS 2. This optimized route 
proved more efficient and higher yielding than the previous route outlined in Figure 19 as 
it removed intermediate deprotection–reprotection steps. 
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Figure 20. Upper. Modified scheme for the synthesis of 2 via key nucleophilic aromatic substitution.a 
Lower. Final optimized scheme for the synthesis of 2.b 
aReaction Conditions: (a) THF, 22 °C, 2 h; (b) BnNH2, THF, 22 °C, 10 min; (c) NaH, THF, 22 °C, 30 min, 
38% over three steps; (d) H2 (40 psi), Pd/C, AcOH, MeOH, 1 h, 32%; (e [hypothetical]) NaH, MOMCl, 
DMF, 0 to 22 °C; (f [hypothetical]) PPh3, DIAD, THF, 22 °C; (g [hypothetical]) 80% aq TFA, 0 °C. 
bReaction Conditions: (a) THF, 22 °C, 10 min, 85% over two steps; (b) NaH, THF, 22 °C, 1 h, 51%; (c) 
PPh3, DIAD, THF, 22 °C, 85%; (d) H2 (40 psi), Pd/C, AcOH, MeOH, 22 °C, 4 h, 58%; (e) 80% aq TFA, 0 
°C, 19 h, 70%. 
 
Given the facile cyclization of enaminone 40 via nucleophilic aromatic substitution, it 
was envisioned that an oxime derivative of β-ketosulfonamide 34 could also easily 
cyclize to afford the Mitsunobu nucleophile for the synthesis of benzoxazinone-AMS 3 
(Figure 21). Reaction of 34 with sodium nitrite under acidic conditions afforded oxime 
52,47 which was cyclized under mildly basic conditions with cesium carbonate48 to 
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provide benzoxazinone-sulfonamide 53. Mitsunobu coupling with adenosine 9 provided 
penultimate benzoxazinone-AMS 54, which was subsequently deprotected with aqueous 
TFA to afford 3. 
 
Figure 21. Synthesis of benzoxazinone-AMS 3.a 
aReaction Conditions: (a) NaNO2, AcOH/H2O/THF (1:1:2), 0 °C, 19 h, 74%; (b) Cs2CO3, DMF, 22 °C, 4.5 
h, 58%; (c) PPh3, DIAD, THF, 22 °C, 28.5 h, 45%; (d) 80% aq TFA, 19 h, 81%. 
 
Lastly, attention was turned toward the synthesis of conformationally constrained 
analogue of DHB-AMS, 4. The ease with which β-ketosulfonamide 34 could undergo 
homologation with DMF-DMA and the competitive acid-catalyzed cyclization of 12 
prompted a revisit to the initially proposed synthesis of 1 (Figure 7 above). This route, 
although more steps, could alternatively provide a higher yield of 1 as well as its 8″-
hydroxy variant 4 (Figure 22). The necessary β-ketosulfonamide to test this hypothesis 
was synthesized from DHBA, which was esterified with SOCl2 in refluxing methanol.49 
TBS was chosen as protecting group for the hydroxyl functionalities based on its ability 
to be removed under fairly mild conditions. Claisen-like condensation of the 
aforementioned N-Boc-methanesulfonamide 36 with ester 5617 resulted in the formation 
of two primary products: the bis-silyl ether shown and a mono-deprotected variant, both 
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isolable after workup and flash chromatography. To ease the purification process, and 
because the hydroxyl protection was no longer necessary, the crude material from 
reaction workup was directly subjected to TBAF deprotection, affording β-
ketosulfonamide 58 in an acceptable 82% yield over the two discrete steps. 
Homologation with DMF-DMA to 5925 and cyclization via acidic wash of the reaction24 
provided 8-hydroxy chromone sulfonamide 60. Mitsunobu coupling with the unprotected 
hydroxyl group proved nontrivial, so it was protected as its MOM ether 61.50 Reaction 
with adenosine 9 afforded fully protected 62, which was deprotected under aqueous TFA 
conditions to yield the desired 8″-hydroxy chromone-AMS 4. 
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Figure 22. Synthesis of 8″-OH chromone-AMS 4a and revised synthesis of chromone-AMS 1.b 
aReaction Conditions for 4: (a) SOCl2, MeOH, 80 °C, 21 h, 90%; (b) TBSCl, imidazole, DMF, 60 °C, 99%; 
(c) LDA, THF, 0 °C, 2 h; (d) TBAF, THF, 0 °C, 1.5 h, 82% over two steps; (e) THF, 22 °C, 18 h; (f) Satd 
aq NH4Cl, 79% over two steps; (g) MOMCl, DIPEA, DCM, 0 to 22 °C, 22 h, 58%; (h) PPh3, DIAD, THF, 
22 °C, 4.5 h, 28%; (i) 80% aq TFA, 0 °C, 24 h, 5%. 
bReaction Conditions for 1: (a) Not applicable; (b) TBSCl, imidazole, DMAP, DMF, 0 to 22 °C, 21.5 h, 
79%; (c) LDA, THF, 0 °C, 3 d; (d) TBAF, THF, 0 °C, 17 h, 86% over two steps; (e) THF, 22 °C, 18 h; (f) 
Satd aq NH4Cl, 74% over two steps; (g) Not applicable; (h) As before (see Figure 11); (i) As before (see 
Figure 11). 
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Biochemical Evaluation. 
The compounds were evaluated for their binding to MbtA as well as related AAAEs 
BasE, EntE, and VibE (from A. baumannii, E. coli, and V. cholerae respectively) through 
employment of a fluorescence polarization (FP) assay developed in our laboratory (Table 
3).51 This assay is a competitive binding assay in which our probe molecule Fl-Sal-AMS 
(courtesy João Neres, Figure 23) is displaced from its binding site with addition of 
inhibitory compounds. The experimental data affords the KD for each compound. 
 MbtA KD (µM) 
BasE 
KD (µM) 
EntE 
KD (µM) 
VibE 
KD (µM) 
Fl-Sal-AMS 0.0093b 0.093 0.23 0.13 
1 3.6 ± 0.1 108 ± 8 280 ± 60 98 ± 7 
2 0.0024 ± 0.0001 0.029 ± 0.002 0.32 ± 0.04 0.017 ± 0.002 
3 0.37 ± 0.01 1.19 ± 0.07 12 ± 1 2.5 ± 0.7 
4 290 ± 70 >290 >290 >290 
 
Table 3. KD values determined against MbtA and other AAAEs.a 
aAssays performed by/with Daniel J. Wilson. 
bPreviously reported51 with assay development. 
 
 
Figure 23. Structure of FP Probe Fl-Sal-AMS. 
 
For those compounds yielding KD values below that of the FP probe, only 2 in this case, 
our lab employs a [32P]PPi-ATP exchange assay that takes advantage of the equilibrium 
nature of MbtA’s adenlyation half-reaction.18 Here, compound 2 afforded a Kiapp of 120 ± 
20 nM. 
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Although disheartening, the enzymatic data for 1–3 do align with previous SAR 
findings of Sal-AMS-based inhibitors. When the linker region of Sal-AMS was 
investigated, significant losses in potency were seen with complete removal of the parent 
sulfamate negative charge.14,17 The total absence of negative character from both 
chromone 1 and benzoxazinone 3 is reflected in their approximately 400- and 40-fold 
losses in binding affinity versus that of the FP probe respectively. The higher affinity of 
benzoxazinone 3 versus 1 is most likely due to its more isosteric design when compared 
to the likely bound conformation of Sal-AMS. Quinolone 2 reintroduces the seemingly 
necessary partial negative charge through its acidic quinolone nitrogen, however 
possesses an 18-fold loss in [32P]PPi-ATP exchange assay activity versus that of Sal-
AMS. These notions are further supported by the results from the other AAAEs tested 
because the trends align with MbtA. A surprising find of the FP assay was the complete 
lack of activity of compound 4. Such an outcome was expected for MbtA as the substrate 
it accepts is SAL but rescued potency was expected for the remaining AAAEs because 
their accepted substrate is DHBA. A hypothesis explaining this disparity could be the 
compound’s inability to achieve the predicted binding mode to thereby mimic the bound 
conformation as observed structurally (see Figure 4 above). 
Antitubercular Evaluation. 
The compounds were tested against Mtb under iron-deficient and iron-replete 
conditions as previously described (Table 4).14 
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 Iron-deficient 
(GAST) 
Iron-replete 
(GAST/Fe) 
INHa 0.11 0.11 
Sal-AMSb 0.39 1.56 
1 >50 >50 
2 >50 >50 
3 >50 >50 
4 >50 >50 
 
Table 4. MIC99 determined against Mtb clinical isolate H37Rv (µM).c 
aINH is isoniazid positive control. 
bPreviously reported.14 
cAssays performed by Helena I. Boshoff. 
 
Unexpectedly, compounds 1–3 all showed total losses in appreciable activity. Although 
the partial negative charge afforded by quinolone 2 rescued its enzymatic potency versus 
1 and 3, it still lacked activity seen with Sal-AMS-based inhibitors containing charged 
linker moieties. As expected and demonstrated by loss of enzymatic potency in FP assay, 
compound 4 also showed almost no appreciable whole cell activity. It is hypothesized 
that unknown intracellular mechanisms and/or metabolism are responsible for the total 
loss of activity seen with 1–3, thereby preventing the compounds from reaching their 
desired target. It is believed that cellular penetration issues are not responsible for the loss 
of activity; the increased lipophilicity of 1–3 should preclude that conclusion because 
charged parent Sal-AMS has substantial whole cell activity. 
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Conclusion and Potential Future Directions 
Herein has been reported the synthesis, biochemical and antitubercular evaluation of 
conformationally constrained analogues of Sal-AMS 1–3, as well as synthesis of DHB 
variant 4. A concise synthesis to each has been developed whereby aryl β-
ketosulfonamides are rapidly elaborated and coupled to appropriately protected adenosine 
via Mitsunobu reaction. Compounds 1–3 displayed low- to sub-micromolar binding to 
MbtA in our FP assay. Subsequent analysis of 2 showed 18-fold loss in potency versus 
that of Sal-AMS in our PPi exchange assay. Unexpectedly, 1–3 displayed >130-fold loss 
in potency versus Sal-AMS in our whole cell assay under relevant iron-limiting 
conditions, even though the partial negative charge afforded by quinolone 2 somewhat 
rescued its enzymatic potency. All that considered, the syntheses of 2 and 3 provided a 
generalizable, higher-yielding route to 1 and sparked inspiration and interest in the 
synthesis of 4. Based on our collaborators’ previous crystallographic successes with BasE 
from A. baumannii, a co-crystal structure of 2 with BasE could provide necessary insight 
for the binding mode of these conformationally constrained analogues of Sal-AMS. 
Furthermore, the pKa of quinolone 2 could be experimentally determined and 
subsequently modulated through appropriate installation of electron-withdrawing groups 
about the aryl ring of the compound. This would allow a detailed dissection of the role 
the acidic quinolone plays in binding affinity. 
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Experimental Details 
Synthesis. 
General Experimental Procedures. All commercial reagents were used as provided 
unless otherwise indicated. An anhydrous solvent dispensing system (J. C. Meyer) using 
two packed columns of neutral alumina was used for drying THF and CH2Cl2, while two 
packed columns of molecular sieves were used to dry DMF, and the solvents were 
dispensed under Ar. Anhydrous grade MeOH was purchased from Aldrich. Flash 
chromatography was performed using Combiflash Companion equipped with flash 
column silica cartridges with the indicated solvent system. Reversed-phase HPLC (RP-
HPLC) purification was performed on a Phenomenex Gemini 10 micron C18 250 × 10.00 
mm column operating at 5.0 mL/min with detection at 254 nm with the indicated solvent 
system. All reactions were performed under an inert atmosphere of dry Ar in oven-dried 
(150 °C) glassware. 1H, 13C, and 19F NMR spectra were recorded on a Varian 600 MHz 
spectrometer. Proton chemical shifts are reported in ppm from an internal standard of 
residual chloroform (7.26), methanol (3.31), dichloromethane (5.32), dimethyl sulfoxide 
(2.50), or mono-deuterated water (HDO, 4.79); carbon chemical shifts are reported in 
ppm from an internal standard of residual chloroform (77.16), methanol (49.00), 
dichloromethane (54.00), or dimethyl sulfoxide (39.52); and fluorine chemical shifts are 
reported in ppm from an internal standard of 2-fluorobenzoic acid (-112.05).52 Proton 
chemical data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, ovlp = overlapping), coupling 
constant(s), integration. High-resolution mass spectra were obtained on an Agilent TOF 
II TOF/MS instrument equipped with either an ESI or APCI interface. 
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Compounds from Figure 8 
(E)-3-(Dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-1-one (12).24 A solution of 
o-hydroxyacetophenone (6.0 mL, 50 mmol, 1.0 equiv) and N,N-dimethylformamide 
dimethylacetal (8.0 mL, 60 mmol, 1.2 equiv) in o-xylene (50 mL) was refluxed at 160 °C 
for 5 h. The reaction was concentrated in vacuo. Crystallization of the resulting residue in 
toluene afforded the title compound (7.53 g, 79%) as a yellow crystalline solid: Rf 0.39 
(1:1 EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 2.93 (s, 3H), 3.15 (s, 3H), 5.75 (d, J 
= 12.0 Hz, 1H), 6.80 (t, J = 7.8 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H), 7.33 (t, J = 7.8 Hz, 
1H), 7.68 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 12.0 Hz, 1H), 13.97 (s, 1H); 13C NMR (150 
MHz, CDCl3) δ 37.5, 45.5, 90.1, 105.8, 118.1, 118.3, 120.4, 128.3, 134.0, 154.9, 163.0, 
191.5; HRMS (APCI–) calcd for C11H12NO2– [M – H]– 190.0874, found 190.0880 (error 
3.2 ppm). 
Chromone-3-sulfonamide (7). To a stirred solution of recrystallized sulfamoyl 
chloride 1432 (347 mg, 3.00 mmol, 1.00 equiv) in DCM (6 mL) at 0 °C was added 
enaminone 12 (574 mg, 3.00 mmol, 1.00 equiv) in one portion. After stirring 5 h, reaction 
was quenched with addition of satd aq NaHCO3 (50 mL). The layers were separated and 
aqueous pH adjusted to neutral (~7 by pH paper). The aqueous was then extracted with 
EtOAc (3 × 75 mL). The combined organic layer was dried (MgSO4), concentrated, and 
chromatographed (20:80 to 40:60 EtOAc/hexanes gradient) yielding cyclized chromone 
13 (140 mg, 32%; characterization data matched that of authentic commercially obtained 
sample) and starting enaminone 12 (86 mg, 15%). LRMS showed the possibility of 
product remaining in the aqueous layer (saw principle peak of m/z = 224 in negative 
mode), so the aqueous was further extracted with n-BuOH (3 × 75 mL). The combined n-
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BuOH layer was dried (MgSO4) and concentrated. The resultant residue was taken up in 
MeOH/MeCN and insoluble solids filtered away. Upon sitting overnight, a precipitate 
had formed in the MeOH/MeCN filtrate. Isolation and drying of that precipitate afforded 
the title compound (34 mg, 5%) as off-white crystals: 1H NMR (600 MHz, D2O) δ 7.60 
(t, J = 7.6 × 2 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.90 (ddd, J = 8.5, 7.6, 1.5 Hz, 1H), 8.21 
(dd, J = 7.6, 1.5 Hz, 1H), 8.84 (s, 1H); LRMS (ESI–) calcd for C9H6NO4S– [M – H]– 224, 
found 224. 
Compounds from Figure 9 
N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-
ylsulfonyl]azanide (15).33 To a stirred solution of t-BuOH (1.04 g, 14.0 mmol, 1.00 
equiv) in DCM (10 mL) at 0 °C was added chlorosulfonyl isocyanate (1.2 mL, 14 mmol, 
1.0 equiv) dropwise. The solution was stirred 5 min. DMAP (3.42 g, 28.0 mmol, 2.00 
equiv) was added to the solution in one portion causing gas evolution and precipitate 
formation. The reaction mixture was maintained at 0 °C a further 10 min then was 
allowed to warm to 22 °C and stirred an addition 1.5 h. The mixture was diluted with 
DCM (25 mL) and was washed with H2O (3 × 50 mL), dried (MgSO4), and concentrated 
to an amorphous off-white solid. Recrystallization of the solid from MeCN afforded the 
title compound (1.63 g, 38%) as off-white crystals: Characterization data matched that as 
reported. The concentrated mother liquor could likely have been recrystallized, however 
this was not pursued because more than enough material was in hand for use. 
N-(Benzyloxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-
ylsulfonyl]azanide (16).34 To a stirred solution of BnOH (1.45 mL, 14.0 mmol, 1.00 
equiv) in DCM (10 mL) at 0 °C was added chlorosulfonyl isocyanate (1.2 mL, 14 mmol, 
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1.0 equiv) dropwise. The solution was stirred 5 min. DMAP (3.42 g, 28.0 mmol, 2.00 
equiv) was added to the solution in one portion causing gas evolution and precipitate 
formation. The reaction mixture was maintained at 0 °C a further 10 min then was 
allowed to warm to 22 °C and stirred an addition 1.5 h. The mixture was diluted with 
DCM (25 mL) and was washed with H2O (3 × 50 mL), dried (MgSO4), and concentrated 
to an amorphous off-white solid. Recrystallization of the solid from MeCN afforded the 
title compound (4.02 g, 85%) as off-white crystals: Characterization data matched that as 
reported. The concentrated mother liquor could likely have been recrystallized, however 
this was not pursued because more than enough material was in hand for use. 
Chromone (13) via attempted reaction of enaminone 12 with Boc-protected 
sulfamoylating reagent 15. To a solution of enaminone 12 (19 mg, 0.10 mmol, 1.0 equiv) 
in DCM (1 mL) at 22 °C was added sulfamoylating reagent 15 (30 mg, 0.10 mmol, 1.0 
equiv). After 8 h stirring at 22 °C, TLC monitoring showed no reaction progress, so 
reaction temperature increased to 40 °C. After 16 h stirring at 40 °C, TLC still showed no 
reaction progress. DCM was removed in vacuo and replaced with dioxane (1 mL). The 
solution was heated at 80 °C. After 24 h stirring, TLC showed total consumption of 
enaminone 12 and sole formation of chromone 13 as verified by LRMS ([ESI+] calcd for 
C9H7O2+ [M + H]+ 147, found 147). 
Chromone (13) via attempted reaction of enaminone 12 with Cbz-protected 
sulfamoylating reagent 16. To a solution of enaminone 12 (19 mg, 0.10 mmol, 1.0 equiv) 
in DCM (1 mL) at 22 °C was added sulfamoylating reagent 16 (30 mg, 0.10 mmol, 1.0 
equiv). After 8 h stirring at 22 °C, TLC monitoring showed no reaction progress, so 
reaction temperature increased to 40 °C. After 16 h stirring at 40 °C, TLC still showed no 
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reaction progress. DCM was removed in vacuo and replaced with dioxane (1 mL). The 
solution was heated at 80 °C. After 24 h stirring, TLC showed total consumption of 
enaminone 12 and sole formation of chromone 13 as verified by LRMS ([ESI+] calcd for 
C9H7O2+ [M + H]+ 147, found 147). 
Compounds from Figure 11 
tert-Butyl chlorosulfonylcarbamate (17).33 To a stirred solution of tert-butanol (1.9 
mL, 20 mmol, 1.3 equiv) in DCM (12 mL) at 0 °C was added chlorosulfonyl isocyanate 
(1.4 mL, 15 mmol, 1.0 equiv) dropwise over the course of 10 min. The reaction was 
removed from the 0 °C bath after 5 min of additional stirring. After warming to 22 °C, 
stirring was stopped and the reaction was concentrated in vacuo just until precipitate 
formation was observed. The flask was placed back into the 0 °C bath. After 50 min, the 
precipitate was filtered and washed with hexanes yielding the title compound (1.5 g, 
46%) as a colorless solid. More product (1.2 g, 37%) was obtained by crystallizing the 
concentrated mother liquor in DCM at 0 °C. The precipitate was used directly without 
further purification: 1H NMR (600 MHz, CD2Cl2) δ 1.56 (s, 9H), 8.50 (s, 1H). 
tert-Butyl (chromon-3-yl)sulfonylcarbamate (8).30 To a stirred solution of Boc-
protected sulfamoyl chloride 17 (1.5 g, 7.0 mmol, 1.0 equiv) in DCM (14 mL) at 22 °C 
was added enaminone 12 (1.3 g, 7.0 mmol, 1.0 equiv). The reaction was stirred 13 h then 
concentrated in vacuo. Purification by flash chromatography (30:70 to 100:0 
DCM/hexanes gradient) afforded the title compound (377 mg, 21%) as a yellow 
amorphous solid: Rf 0.29 (1:5:95 Et3N/MeOH/DCM); 1H NMR (600 MHz, CDCl3) δ 1.40 
(s, 9H), 7.54 (t, J = 7.8 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.80 (t, J = 8.3 Hz, 1H), 8.27 
(d, J = 7.8 Hz, 1H), 8.82 (s, 1H); 13C NMR (150 MHz, CDCl3) δ 28.0, 84.4, 118.9, 123.6, 
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124.4, 126.4, 127.1, 135.4, 149.2, 156.3, 162.0, 171.8; HRMS (ESI–) calcd for 
C14H14NO6S– [M – H]– 324.0547, found 324.0559 (error 3.7 ppm). 
N6,N6-Bis(tert-butoxycarbonyl)-2′,3′-O-isopropylideneadenosine (9).29 To a stirred 
solution of 2′,3′-O-isopropylideneadenosine 18 (5.00 g, 16.3 mmol, 1.00 equiv) in DMF 
(50 mL) at 0 °C was added imidazole (2.83 g, 41.6 mmol, 2.55 equiv) followed by 
TBSCl (2.95 g, 19.6 mmol, 1.20 equiv). After 4 h the reaction was warmed to 22 °C and 
the mixture was concentrated. The resulting residue was partitioned between EtOAc (200 
mL) and H2O (100 mL). The organic layer was washed with H2O (100 mL) and satd 
NaCl (50 mL), dried (MgSO4), filtered, and concentrated. Purification by flash 
chromatography (0:100 to 100:0 EtOAc/hexanes gradient) afforded 5′-O-tert-
butyldimethylsilyl-2′,3′-O-isopropylideneadenosine 19 in quantitative yield as an off-
white solid: Rf 0.39 (4:1 EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 0.015 (s, 3H), 
0.022 (s, 3H), 0.85 (s, 9H), 1.41 (s, 3H), 1.64 (s, 3H), 3.77 (dd, J = 11.4, 4.2 Hz, 1H), 
3.88 (dd, J = 11.4, 4.2 Hz, 1H), 4.42 (q, J = 4.2 Hz, 1H), 4.96 (dd, J = 6.6, 3.0 Hz, 1H), 
5.29 (dd, J = 6.0, 2.4 Hz, 1H), 5.71 (br s, 2H), 6.17 (d, J = 3.0 Hz, 1H), 8.05 (s, 1H), 8.38 
(s, 1H). 
To a stirred solution of adenosine derivative 19 (6.87 g, 16.3 mmol, 1.00 equiv) 
prepared above, DMAP (418 mg, 3.42 mmol, 0.210 equiv) and Et3N (4.8 mL, 34 mmol, 
2.1 equiv) in DMF (150 mL) at 0 °C was added Boc2O (7.46 g, 34.2 mmol, 2.10 equiv) in 
one portion. After 1 h the reaction was warmed to 22 °C. Reaction monitoring by TLC 
showed no noticeable change over 18 h of stirring at 22 °C. More DMAP (219 mg, 1.79 
mmol, 0.110 equiv) and Et3N (2.5 mL, 18 mmol, 1.1 equiv) were added and the solution 
cooled to 0 °C. More Boc2O (3.91 g, 17.9 mmol, 1.10 equiv) was added and the solution 
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was allowed to warm to 22 °C of its own accord while stirring for a further 26 h. The 
reaction was then concentrated yielding a thick brown oil (12.58 g). Purification by flash 
chromatography (20:80 EtOAc/hexanes) afforded N6,N6-bis(tert-butoxycarbonyl)-5′-O-
tert-butyldimethylsilyl-2′,3′-O-isopropylideneadenosine 20 (8.81 g, 87%) as an off-white 
solid: Rf 0.73 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.02 (s, 6H), 0.85 (s, 
9H), 1.41 (s, 3H), 1.44 (s, 18H), 1.65 (s, 3H), 3.78 (dd, J = 11.4, 4.1 Hz, 1H), 3.89 (dd, J 
= 11.4, 3.7 Hz, 1H), 4.45 (ap q, J = 3.7 Hz, 1H), 4.96 (dd, J = 6.3, 2.5 Hz, 1H), 5.22 (dd, 
J = 6.1, 2.5 Hz, 1H), 6.25 (d, J = 2.5 Hz, 1H), 8.34 (s, 1H), 8.88 (s, 1H). 
To a stirred solution of silyl ether 20 (7.35 g, 11.8 mmol, 1.00 equiv) prepared above 
in THF (100 mL) was added TBAF (16 mmol, 1.4 equiv) in one portion. The solution 
was concentrated in vacuo after 1.5 h. Purification by flash chromatography (50:50 to 
70:30 EtOAc/hexanes gradient) afforded the title compound (5.05 g, 84%) as an off-
white solid: Rf 0.33 (1:2 acetone/hexanes); 1H NMR (600 MHz, DMSO-d6) δ 1.34 (s, 
3H), 1.39 (s, 18H), 1.56 (s, 3H), 3.53 (ap q, J = 8.8, 4.7 Hz, 2H), 4.29 (ap q, J = 6.5, 4.1 
Hz, 1H), 5.00 (dd, J = 5.9, 2.4 Hz, 1H), 5.11 (t, J = 5.3 Hz, 1H), 5.45 (dd, J = 5.9, 2.4 Hz, 
1H), 6.29 (d, J = 2.4 Hz, 1H), 8.82 (s, 1H), 8.88 (s, 1H). 
N6,N6-Bis(tert-butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -
(chromon-3-yl)sulfonyl- 2′,3′-O-isopropylideneadenosine (10). To a stirred solution of 
Boc-protected chromone sulfonamide 8 (270 mg, 0.83 mmol, 1.1 equiv), bis-Boc 
adenosine 9 (381 mg, 0.75 mmol, 1.0 equiv) and PPh3 (218 mg, 0.83 mmol, 1.1 equiv) in 
THF (20 mL) at 0 °C was added DIAD (0.16 mL, 0.83 mmol, 1.1 equiv) dropwise over 
the course of 10 min. The reaction was stirred 2.5 h at 0 °C and was then allowed to 
warm to 22 °C. The reaction was stirred another 1.5 h then was concentrated in vacuo. 
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Purification by flash chromatography (40:60 EtOAc/hexanes) afforded the title 
compound (491 mg, 80%) as a colorless oil: Rf 0.63 (3:1 EtOAc/hexanes); 1H NMR (600 
MHz, CDCl3) δ 1.25 (s, 3H), 1.34 (s, 9H), 1.41 (s, 18H), 1.65 (s, 3H), 4.25 (dd, J = 15.3, 
6.5 Hz, 1H), 4.36 (dd, J = 15.3, 6.5 Hz, 1H), 4.67 (td, J = 6.5 × 2, 3.5 Hz, 1H), 5.21 (dd, J 
= 6.2, 3.5 Hz, 1H), 5.42 (dd, J = 6.2, 2.3 Hz, 1H), 6.23 (d, J = 2.3 Hz, 1H), 7.51 (t, J = 
7.9 × 2 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.77 (ddd, J = 8.5, 7.9, 1.5 Hz, 1H), 8.19 (dd, J 
= 7.9, 1.5 Hz, 1H), 8.28 (s, 1H), 8.69 (s, 1H), 8.91 (s, 1H); 13C NMR (150 MHz, CDCl3) 
δ 25.6, 27.4, 27.9, 28.0, 49.5, 82.5, 83.8, 84.6, 85.2, 85.5, 90.8, 114.9, 118.7, 124.4, 
125.4, 126.3, 127.1, 129.1, 129.6, 135.2, 144.1, 150.4, 150.58, 150.61, 152.4, 152.7, 
161.8, 171.3; HRMS (ESI+) calcd for C37H47N6O13S+ [M + H]+ 815.2916, found 
815.2926 (error 1.2 ppm). 
5′-Amino-5′-N-[(chromon-3-yl)sulfonyl]adenosine (1). To Mitsunobu product 10 at 
0 °C was added ice-cold 80% aq TFA (5 mL). Reaction was allowed to warm to 22 °C 
after 1.5 h stirring and was stirred an additional 3 h. The reaction was concentrated in 
vacuo and subsequent purification by flash chromatography (10:90 MeOH/CHCl3) 
afforded the title compound (210 mg, 76%) as a colorless amorphous solid: Rf 0.33 (1:9 
MeOH/CHCl3); 1H NMR (600 MHz, 1:10 D2O/DMSO-d6) δ 3.20 (dd, J = 14.1, 3.5 Hz, 
1H), 3.27 (dd, J = 14.1, 4.7 Hz, 1H), 4.05 (m, 1H), 4.07 (dd, J = 5.0, 1.6 Hz, 1H), 4.68 
(td, J = 6.4 × 2, 1.6 Hz, 1H), 5.74 (d, J = 6.4 Hz, 1H), 7.53 (t, J = 7.6 × 2 Hz, 1H), 7.64 
(d, J = 7.6 Hz, 1H), 7.84 (td, J = 7.6 × 2, 1.2 Hz, 1H), 8.05 (dd, J = 7.6, 1.2 Hz, 1H), 8.22 
(s, 1H), 8.26 (s, 1H), 8.83 (s, 1H); 13C NMR (150 MHz, DMSO-d6) δ 45.0, 71.3, 72.3, 
84.0, 88.3, 118.7, 119.6, 123.7, 124.3, 125.2, 126.5, 135.1, 140.5, 148.6, 152.5, 155.6, 
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156.2, 160.3, 171.6; HRMS (ESI+) calcd for C19H19N6O7S+ [M + H]+ 475.1030, found 
475.1025 (error 1.1 ppm). 
Compounds from Figure 12 
Benzyl (2-acetylphenyl)carbamate (22).36 To a solution of o-aminoacetophenone 21 
(1.2 mL, 10 mmol, 1.0 equiv), pyridine (3.2 mL, 40 mmol, 4.0 equiv), and DMAP (61 
mg, 0.50 mmol, 0.050 equiv) in DCM (30 mL) at 0 °C was added benzyl chloroformate 
(2.9 mL, 20 mmol, 2.0 equiv) dropwise over 25 min. After 30 min stirring at 0 °C, H2O 
(10 mL) was added to the mixture. The layers were separated and the aqueous extracted 
with EtOAc (2 × 20 mL). The combined organic layer was washed with satd aq NaCl 
(100 mL), dried (MgSO4), and concentrated. Purification by flash chromatography (50:50 
to 100:0 EtOAc/hexanes gradient) afforded the title compound (2.69 g, quant.) as a pale 
yellow amorphous solid: Characterization data matched that as reported.53 
(E)-Benzyl (2-(3-(dimethylamino)acryloyl)phenyl)carbamate (23). A solution of 
acetophenone 22 (1.89 g, 7.00 mmol, 1.00 equiv) and N,N-dimethylformamide 
diethylacetal (1.5 mL, 8.4 mmol, 1.2 equiv) in o-xylene (58 mL) in a flask topped with a 
short-path distillation apparatus was heated at 160 °C. After 15 min, the solution had 
gone from colorless to yellow and distillate (presumably EtOH side product) began 
collecting in the receiving flask. Heating was continued a further 15 min then was 
stopped. Precipitate formed upon sitting at 22 °C overnight. The precipitate was removed 
by filtration and the resultant solution concentrated. Recrystallization of the solid from 
toluene afforded the title compound (724 mg, 32%) as golden yellow crystals; the mother 
liquor was concentrated. Recrystallization of that solid from toluene afforded more of the 
title compound (299 mg, 13%) as golden yellow crystals: Rf 0.24 (1:99 MeOH/DCM); 1H 
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NMR (600 MHz, CDCl3) δ 2.92 (s, 3H), 3.16 (s, 3H), 5.19 (s, 2H), 5.66 (d, J = 12.0 Hz, 
1H), 7.01 (t, J = 7.6 × 2 Hz, 1H), 7.30–7.41 (ovlp m, 5H), 7.72 (d, J = 7.6 Hz, 1H), 7.77 
(d, J = 12.0 Hz, 1H), 8.36 (d, J = 8.8 Hz, 1H), 11.36 (s, 1H); LRMS (APCI–) calcd for 
C19H19N2O3– [M – H]– 323, found 323. 
(E)-Benzyl (2-(3-(dimethylamino)acryloyl)phenyl)carbamate (23) recovered from 
attempted synthesis of benzyl 3-(N-(tert-butoxycarbonyl)sulfamoyl)-4-oxoquinoline-
1(4H)-carboxylate (24) via enaminone 23 and Boc-protected sulfamoyl chloride 17. To a 
solution of Boc sulfamoyl chloride 17 (474 mg, 2.10 mmol, 1.50 equiv) in DCM (6 mL) 
at 0 °C was added enaminone 23 (454 mg, 1.40 mmol, 1.00 equiv) in one portion. After 
30 min, TLC showed no reaction progress, so the solution was allowed to warm to 22 °C 
of its own accord overnight. After 16 h, the reaction was quenched with addition of satd 
aq NaHCO3 (10 mL). The layers were separated and the aqueous extracted with EtOAc 
(3 × 25 mL). The combined organic layer was dried (MgSO4) and concentrated affording 
starting enaminone 23 (428 mg, 94%): Characterization data matched that as given 
above. 
Compounds from Figure 17 
Methyl 2-fluorobenzoate (35). To 2-fluorobenzoic acid (1.4 g, 10 mmol, 1.0 equiv) 
in methanol (20 mL) was added a catalytic amount of concentrated H2SO4. The solution 
was heated at 75 °C. After 19 h, the solution was cooled to 0 °C and the acid quenched by 
addition of solid NaHCO3 (1.5 g). The mixture was concentrated in vacuo, taken up in 
EtOAc (10 mL) and filtered away from the insoluble material. Concentration of the 
EtOAc yielded the title compound (1.36 g, 88%) as a colorless oil, used directly without 
further purification: Rf 0.64 (1:9 EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 3.93 (s, 
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3H), 7.13 (m, 1H), 7.20 (ap t, J = 7.6 Hz, 1H), 7.52 (ap q, J = 7.6 Hz, 1H), 7.93 (ap t, J = 
7.6 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 52.4, 117.1 (d, 2JC-F = 23.1 Hz), 118.8 (d, 
2JC-F = 10.4 Hz), 124.1 (d, 3JC-F = 4.6 Hz), 132.3, 134.6 (d, 3JC-F = 9.2 Hz), 162.0 (d, 1JC-F 
= 258.9 Hz), 165.0 (d, 3JC-F = 4.6 Hz); 19F NMR (564 MHz, CDCl3) δ -113.4; HRMS 
(APCI+) calcd for C8H8FO2+ [M + H]+ 155.0503, found 155.0513 (error 6.4 ppm). 
tert-Butyl methylsulfonylcarbamate (36).17,28 To a stirred suspension of 
methanesulfonamide (238 mg, 2.50 mmol, 1.00 equiv), Et3N (0.38 mL, 2.8 mmol, 1.1 
equiv), and DMAP (30 mg, 0.25 mmol, 0.10 equiv) in DCM (5 mL) at 22 °C was added a 
solution of Boc2O (654 mg, 3.00 mmol, 1.20 equiv) in DCM (2 mL) dropwise over 10 
min. After 2 h stirring, the reaction was concentrated to an oily residue. The residue was 
taken up in EtOAc (15 mL). The organic layer was washed with 1 N HCl (10 mL), H2O 
(15 mL), and satd aq NaCl (15 mL), dried (MgSO4) and concentrated affording the title 
compound (454 mg, 93%) as an off-white amorphous solid: Characterization data 
matched that as reported. 
tert-Butyl (2-(2-fluorophenyl)-2-oxoethyl)sulfonylcarbamate (34).17 Freshly titrated 
n-BuLi (2.1 M in hexane, 12.4 mL, 26.1 mmol, 3.10 equiv) was added dropwise to 
freshly distilled (i-Pr)2NH (3.9 mL, 27.8 mmol, 3.30 equiv) in THF (24 mL) at 0 °C. The 
mixture was stirred for 1 h, then sulfonamide 36 (1.65 g, 8.43 mmol, 1.00 equiv) in THF 
(24 mL) was added and the reaction stirred for a further 1 h at 0 °C. Next, methyl ester 35 
(1.43 g, 9.28 mmol, 1.10 equiv) in THF (5 mL) was added and the reaction was stirred 
for 1.5 h at 0 °C. The reaction mixture was quenched with satd aq NaCl (25 mL) and 0.5 
M aq NaH2PO4 (25 mL). The layers were separated and the aqueous layer acidified to pH 
~5-6 (pH paper) with aq 6 N HCl. The aqueous was then extracted with EtOAc (3 × 75 
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mL). The organic layers were combined, dried (MgSO4), and concentrated under reduced 
pressure. Purification by flash chromatography (0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/ 
hexanes) afforded the title compound (1.92 g, 72%) as a yellow solid: Rf 0.74 
(0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 1.50 (s, 
9H), 5.03 (s, 2H), 7.19 (m, 1H), 7.29 (ap t, J = 7.6 Hz, 1H), 7.62 (m, 1H), 7.91 (ap t, J = 
7.6 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 28.1, 61.6 (d, 2JC-F = 9.2 Hz), 85.0, 117.2 (d, 
2JC-F = 23.1 Hz), 124.3, 125.1 (d, 3JC-F = 3.5 Hz), 131.2, 136.6 (d, 3JC-F = 9.2 Hz), 149.6, 
162.2 (d, 1JC-F = 256.6 Hz), 186.2 (d, 3JC-F = 3.5 Hz); 19F NMR (564 MHz, CDCl3) δ -
112.7; HRMS (ESI–) calcd for C13H15FNO5S– [M – H]– 316.0660, found 316.0654 (error 
1.9 ppm). 
Compound from Figure 18 
Ethyl N-(1-ethoxy-3-(2-fluorophenyl)-3-oxoprop-1-en-2-yl)sulfonylformimidate 
(38).39 To a solution of β-ketosulfonamide 34 (64 mg, 0.20 mmol, 1.0 equiv) in Ac2O 
(3.8 mL, 40 mmol, 200 equiv) at 22 °C was added triethyl orthoformate (0.33 mL, 2.0 
mmol, 10 equiv). After 30 min, TLC monitoring showed no reaction progress. The 
reaction was then heated at 77 °C. TLC monitoring (at 15 min, 30 min, and 1.5 h) still 
showed no reaction progress. The reaction was then heated at 90 °C. TLC monitoring (at 
30 min, 1 h, and 1.5 h) showed reaction progress. A further 6 h stirring at 90 °C showed 
total consumption of starting ketosulfonamide 34 by TLC. The reaction was concentrated 
yielding a brown oil (75 mg). Purification by flash chromatography (30:70 
EtOAc/hexanes) afforded the title compound (33 mg, 50%): 1H NMR (600 MHz, CDCl3) 
δ 1.16 (t, J = 7.0 Hz, 3H), 1.29 (t, J = 7.4 Hz, 3H), 4.17 (q, J = 7.0 Hz, 2H), 4.20 (q, J = 
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7.4 Hz, 2H), 7.07 (ap t, J = 9.4 × 2 Hz, 1H), 7.20 (t, J = 7.3 × 2 Hz, 1H), 7.49 (ap qd, J = 
6.5 × 3, 1.2 Hz, 1H), 7.56 (t, J = 7.3 × 2 Hz, 1H), 7.67 (s, 1H), 8.10 (s, 1H). 
Compounds from Figure 19 
tert-Butyl (3-(2-fluorophenyl)-1-((4-methoxybenzyl)amino)-3-oxoprop-1-en-2-
yl)sulfonylcarbamate (40).25,39 N,N-Dimethylformamide dimethylacetal (136 µL, 1.02 
mmol, 1.20 equiv) was added to a solution of β-ketosulfonamide 34 (269 mg, 0.848 
mmol, 1.00 equiv) in THF (5 mL) at 22 °C. The solution was stirred for 17 h, then was 
concentrated under reduced pressure yielding tert-butyl (1-(dimethylamino)-3-(2-
fluorophenyl)-3-oxoprop-1-en-2-yl)sulfonylcarbamate 39 as a yellow oily residue used 
directly without further purification: Rf 0.25 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 1.46 (s, 9H), 2.80 (s, 
3H), 3.32 (s, 3H), 7.07 (t, J = 8.8 × 2 Hz, 1H), 7.19 (t, J = 7.6 × 2 Hz, 1H), 7.44 (ap qd, J 
= 7.0 × 3, 1.8 Hz, 1H), 7.49 (ap td, J = 7.6 × 2, 1.8 Hz), 7.98 (s, 1H); LRMS (ESI–) calcd 
for C16H20FN2O5S– [M – H]– 371, found 371. 
To a stirred solution of enaminone 39 prepared above in DCM (5 mL) at 22 °C was 
added PMBNH2 (165 µL, 1.27 mmol, 1.50 equiv). After stirring 5 min the reaction was 
concentrated under reduced pressure yielding a golden foamy oil. Purification by flash 
chromatography (0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes) afforded a mixture of 
isomers (~2:1) of the title compound (319 mg, 81%) as an off-white amorphous solid: Rf 
0.70 (0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CD2Cl2) δ 
1.46 (s, 9H), 3.79 (minor, s, 1H), 3.80 (major, s, 2H), 4.39 (minor, d, J = 5.3 Hz, 0.67H), 
4.57 (major, d, J = 5.9 Hz, 1.33H), 6.87 (minor, d, J = 8.2 Hz, 0.67H), 6.93 (major, d, J = 
8.5 Hz, 1.33H), 7.069 (major, t, J = 8.8 Hz, 0.67H), 7.075 (minor, t, J = 8.5 Hz, 0.33H), 
 42 
7.14–7.19 (ovrlp m, 2H), 7.24 (major, t, J = 7.0 Hz, 0.67H), 7.28 (major, d, J = 8.5 Hz, 
1.33H), 7.36–7.40 (ovrlp m, 1H), 7.43 (minor, ap q, J = 7.0 Hz, 0.33H), 7.49 (br s, 1H), 
8.27 (major, d, J = 14.1 Hz, 0.67H), 8.69 (minor, m, 0.33H), 10.97 (major, m, 0.67H); 
13C NMR (150 MHz, CD2Cl2) δ 14.5, 21.3, 28.2, 28.3, 53.6, 54.3, 55.8, 60.8, 83.5, 83.6, 
107.7, 108.5, 114.8, 114.9, 115.8, 116.0, 116.4, 116.6, 124.09, 124.11, 124.99, 125.01, 
128.59, 128.61, 129.3, 129.4, 129.77, 129.80, 132.39, 132.44, 150.2, 150.9, 157.9, 158.3, 
158.4, 159.5, 159.9, 160.2, 160.3, 162.0, 185.4, 188.7; 19F NMR (564 MHz, CDCl3) δ -
119.9 (major), -117.3; HRMS (ESI–) calcd for C22H24FN2O6S– [M – H]– 463.1345, found 
463.1353 (error 1.7 ppm). 
tert-Butyl (1-(4-methoxybenzyl)-quinol-4-on-3-yl)sulfonylcarbamate (41).39 NaH 
(60% dispersion in mineral oil, 48 mg, 1.2 mmol, 2.4 equiv) was added to enaminone 40 
(232 mg, 0.50 mmol, 1.0 equiv) in 1,2-DME (4 mL) at 0 °C. The mixture was stirred 19.5 
h and allowed to warm to 22 °C of its own accord. The reaction was diluted with EtOAc 
(20 mL) and quenched with satd aq NH4Cl (10 mL). The layers were separated and the 
aqueous layer acidified to pH ~4-5 (pH paper) with aq 6 N HCl. The aqueous was then 
extracted with EtOAc (2 × 20 mL). The organic layers were combined, dried (MgSO4), 
and concentrated under reduced pressure yielding an off-white residue (249 mg). 
Purification by flash chromatography (0.4:0.4:39.2:60 HCO2H/MeOH/EtOAc/hexanes) 
afforded the title compound (181 mg, 81%) as an amorphous off-white solid: Rf 0.48 
(0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CD3OD) δ 1.37 (s, 
9H), 3.74 (s, 3H), 5.59 (s, 2H), 6.87 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 7.48 (t, 
J = 7.3 Hz, 1H), 7.70–7.75 (ovlp m, 2H), 8.35 (d, J = 8.2 Hz, 1H), 8.88 (s, 1H); 13C NMR 
(150 MHz, CD3OD) δ 28.2, 55.7, 58.0, 83.7, 115.5, 118.4, 119.4, 127.0, 127.5, 128.0, 
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129.4, 134.7, 141.0, 151.2, 152.4, 161.3, 174.0, 174.2; HRMS (ESI–) calcd for 
C22H23N2O6S– [M – H]– 443.1282, found 443.1277 (error 1.1 ppm). 
Quinol-4-on-3-sulfonamide (42).41 Quinolone sulfonamide 41 (44 mg, 0.1 mmol, 1.0 
equiv) in TFA (2 mL) was heated at 72 °C in a sealed tube for 17 h. The reaction was 
then heated at 100 °C for 23 h. The mixture was allowed to cool to 22 °C and was 
concentrated under reduced pressure yielding a light-brown solid (32 mg). Purification by 
flash chromatography (0:0:100 to 1:10:89 HCO2H/MeOH/CHCl3) afforded the title 
compound (13 mg, 58%) as a colorless residue: 1H NMR (600 MHz, DMSO-d6) δ 6.77 
(br s, 2H), 7.46 (dd, J = 8.2, 7.6 Hz, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.76 (dd, J = 8.2, 7.6 
Hz, 1H), 8.20 (d, J = 8.2 Hz, 1H), 8.50 (s, 1H), 12.46 (br s, 1H); 13C NMR (150 MHz, 
DMSO-d6) δ 119.4, 122.1, 124.8, 125.0, 126.3, 132.8, 140.0, 140.4, 172.1; LRMS (ESI–) 
calcd for C9H7N2O3S– [M – H]– 223, found 223. 
tert-Butyl (1-(tert-butoxycarbonyl)-quinol-4-on-3-yl)sulfonylcarbamate (43).42,43 
To a suspension of quinolone sulfonamide 42 (47 mg, 0.21 mmol, 1.0 equiv) in DCM (2 
mL) was added Et3N (64 µL, 0.46 mmol, 2.2 equiv) and DMAP (5 mg, 0.04 mmol, 0.2 
equiv). Boc2O (100 mg, 0.46 mmol, 2.2 equiv) was added to the suspension at 0 °C. The 
mixture was stirred 15 h and allowed to warm to 22 °C of its own accord, after which 
time it was concentrated under reduced pressure yielding a yellow residue (132 mg). 
Purification by flash chromatography afforded recovered quinolone sulfonamide 42 (5.7 
mg, 12%), mono-protected product 46 (39 mg, 57%, characterization data below), and 
the title compound (16 mg, 18%) as a colorless residue: 1H NMR (600 MHz, CD3OD) δ 
1.37 (s, 9H), 1.74 (s, 9H), 7.58 (dd, J = 7.6 × 2 Hz, 1H), 7.83 (ddd, J = 8.8, 7.6, 1.8 Hz, 
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1H), 8.35 (dd, J = 7.6, 1.2 Hz, 1H), 8.58 (d, J = 8.8 Hz, 1H), 9.20 (s, 1H); LRMS (ESI–) 
calcd for C19H23N2O7S– [M – H]– 423, found 423. 
5′-Amino-5′-N-[((quinol-4-on)-3-yl)sulfonyl]adenosine (2). To a solution of 
adenosine 9 (15 mg, 0.030 mmol, 1.0 equiv), sulfonamide 43 (14 mg, 0.033 mmol, 1.1 
equiv), and PPh3 (8.7 mg, 0.033 mmol, 1.1 equiv) in THF (2 mL) at 0 °C was added 
DIAD (6.5 µL, 0.033 mmol, 1.1 equiv). The reaction was stirred and allowed to warm to 
22 °C of its own accord over 15 h. TLC monitoring of the reaction showed presence of 
remaining 9 and 43. More PPh3 (8.7 mg, 0.033 mmol, 1.1 equiv) followed by DIAD (6.5 
µL, 0.033 mmol, 1.1 equiv) was added to the reaction. TLC monitoring of the reaction 
after 1.5 h additional stirring showed complete consumption of 9. The reaction was 
concentrated to a yellow residue (105 mg). Purification by flash chromatography 
(0.6:0.6:58.8:40 HCO2H/MeOH/EtOAc/hexanes) afforded tris-Boc-protected product 44 
(19 mg, 78%) as a colorless residue: 1H NMR (600 MHz, CDCl3) δ 1.28 (s, 9H), 1.36 (s, 
18H), 1.41 (s, 3H), 1.66 (s, 3H), 4.37 (m [2 ovlp m], 2H), 4.69 (m, 1H), 5.12 (m, 1H), 
5.29 (m, 1H), 6.30 (d, J = 2.3 Hz, 1H), 7.41 (ap t, J = 7.9, 7.6 Hz, 1H) 7.66 (ap t, J = 8.2, 
7.6 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 8.60 (s [2 ovrl s], 2H), 
8.92 (s, 1H); LRMS (ESI+) calcd for C37H48N7O12S+ [M + H]+ 814, found 814. 
Tris-Boc-protected 44 (9.1 mg, 0.011 mmol, 1.0 equiv) prepared above was stirred in 
80% aq TFA (5 mL) at 0 °C for 24 h. Concentration in vacuo yielded a colorless residue 
(7.7 mg). Purification by RP-HPLC (15:85 MeCN/H2O) and lyophilization of appropriate 
fractions afforded the title compound (4.4 mg, 85%, 66% over two steps) as a fluffy 
colorless solid: Rf 0.07 (1:10:89 HCO2H/MeOH/EtOAc); 1H NMR (600 MHz, 1:10 
D2O/DMSO-d6) δ 3.04 (dd, J = 13.8, 4.1 Hz, 1H), 3.10 (dd, J = 13.8, 4.1 Hz, 1H), 4.05 
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(ap br s [ddd], 1H), 4.11 (ap d [dd], J = 4.7 Hz, 1H), 4.72 (ap t, J = 6.4, 4.7 Hz, 1H), 5.28 
(D2O-exchangeable, br s, 1H), 5.44 (D2O-exchangeable, br s, 1H), 5.79 (d, J = 6.4 Hz, 
1H), 7.45 (ap t, J = 7.6, 7.4 Hz, 1H), 7.62 (D2O-exchangeable, br s, 2H), 7.64 (d, J = 7.8 
Hz, 1H), 7.76 (ap t, J = 7.8, 7.4 Hz, 1H), 8.13 (d, J = 7.6 Hz, 1H), 8.30 (ap d [2 ovlp s], 
2H), 8.46 (s, 1H), 12.55 (D2O-exchangeable, d, J = 6.5 Hz, 1H); 13C NMR (150 MHz, 
DMSO-d6) δ 44.9, 71.3, 72.2, 84.0, 88.4, 118.2, 119.1, 119.6, 124.9, 125.2, 126.3, 132.9, 
139.6, 140.6, 142.4, 148.8, 152.6, 156.2, 171.9; HRMS (ESI+) calcd for C19H20N7O6S+ 
[M + H]+ 474.1190, found 474.1181 (error 1.9 ppm). 
Compounds from Figure 20 
tert-Butyl (1-benzyl-quinol-4-on-3-yl)sulfonylcarbamate (45).25,39 N,N-
Dimethylformamide dimethylacetal (399 µL, 3.00 mmol, 1.50 equiv) was added to a 
solution of β-ketosulfonamide 34 (635 mg, 2.00 mmol, 1.00 equiv) in THF (10 mL) at 22 
°C. The solution was stirred for 2 h, then was concentrated under reduced pressure 
yielding enaminone 39 as a yellow oily residue used directly without purification. 
To a stirred solution of enaminone 39 prepared above in THF (6 mL) at 22 °C was 
added BnNH2 (328 µL, 3.00 mmol, 1.50 equiv). After stirring 10 min the reaction was 
concentrated under reduced pressure yielding transamination product (Bn-enaminone 
variant of PMB-enaminone 40) as a golden foamy oil used directly without purification. 
To a stirred solution of Bn-enaminone prepared above in THF (8 mL) at 22 °C was 
added NaH (60% dispersion in mineral oil, 176 mg, 4.40 mmol, 2.20 equiv) portion-wise 
(~10 mg portions) such that noticeable gas evolution had ceased before next addition. 
After stirring 30 min, the reaction was quenched by addition of satd aq NH4Cl (25 mL). 
The aqueous mixture was acidified to pH ~4 (pH paper) with aq 6 N HCl and was then 
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extracted with EtOAc (3 × 25 mL). The organic layers were combined, dried (MgSO4), 
and concentrated under reduced pressure yielding an off-white solid. Purification by flash 
chromatography (0.3:0.3:29.4:70 HCO2H/MeOH/EtOAc/hexanes) afforded the title 
compound (315 mg, 38% over three steps) as an amorphous off-white solid: Rf 0.44 
(0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, DMSO-d6) δ 1.29 
(s, 9H), 5.80 (s, 2H), 7.25-7.35 (ovlp m, 5H), 7.49 (m, 1H), 7.74 (ap d [ovlp m], 2H), 
8.26 (d, J = 7.6 Hz, 1H), 8.99 (s, 1H), 11.60 (D2O-exchangeable, br s, 1H); 13C NMR 
(150 MHz, 1:9 D2O/DMSO-d6) δ 27.9, 56.2, 82.2, 118.6, 126.2, 126.4, 126.8, 126.9, 
128.0, 128.5, 129.2, 129.3, 133.9, 135.9, 139.5, 150.3, 171.3; HRMS (ESI–) calcd for 
C21H21N2O5S– [M – H]– 413.1177, found 413.1174 (error 0.7 ppm). 
tert-Butyl (quinol-4-on-3-yl)sulfonylcarbamate (46). To a Parr flask flushed with Ar 
was added Pd/C (10% by weight, 460 mg, 0.432 mmol, 1.00 equiv), N-benzyl quinolone 
45 (179 mg, 0.432 mmol, 1.00 equiv), anhydrous MeOH (43 mL), and AcOH (27 µL, 
0.48 mmol, 1.1 equiv). The reaction vessel was evacuated, then backfilled with H2 to 40 
psi, and the mixture was shaken at 22 °C for 1 h. The reaction mixture was filtered 
through celite and concentrated to an off-white amorphous solid. Purification by flash 
chromatography (0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes) afforded the title 
compound (46 mg, 32%) as an off-white solid: Rf 0.20 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, DMSO-d6) δ 1.25 (s, 9H), 7.48 
(dd, J = 8.2, 7.0 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.78 (dd, J = 8.2, 7.0 Hz, 1H), 8.18 (d, 
J = 8.2 Hz, 1H), 8.57 (s, 1H), 11.44 (br s, 1H), 12.66 (br s, 1H); 13C NMR (150 MHz, 
DMSO-d6) δ 27.7, 81.3, 117.1, 119.4, 125.3, 125.4, 126.6, 133.3, 139.3, 144.8, 150.4, 
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171.3; HRMS (ESI–) calcd for C14H15N2O5S– [M – H]– 323.0707, found 323.0715 (error 
2.5 ppm). 
tert-Butyl (1-(methoxymethyl)-quinol-4-on-3-yl)sulfonylcarbamate (49).25,39 
Dimethylformamide dimethylacetal (399 µL, 3.00 mmol, 1.50 equiv) was added to a 
solution of β-ketosulfonamide 34 (635 mg, 2.00 mmol, 1.00 equiv) in THF (10 mL) at 22 
°C. The solution was stirred for 1.5 h, then was concentrated under reduced pressure 
yielding enaminone 39 as a yellow oily residue used directly without purification. 
To a stirred solution of enaminone 39 prepared above in THF (6 mL) at 22 °C was 
added BnNH2 (328 µL, 3.00 mmol, 1.50 equiv). After stirring 10 min the reaction was 
concentrated under reduced pressure yielding a golden foamy oil. Purification by flash 
chromatography (0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes) afforded a mixture of 
isomers (~2:1) of the title compound (739 mg, 85% over two steps) as a golden foamy 
oil: Rf 0.13 (0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, 
CDCl3) δ 1.46 (minor, s, 3H), 1.47 (major, s, 6H), 4.47 (minor, d, J = 5.3 Hz, 0.67H), 
4.66 (major, d, J = 5.9 Hz, 1.33H), 6.65 (major, m, 0.67H), 7.10-7.25 (ovlp m, 1H), 7.14-
7.19 (ovlp m, 1H), 7.24 (major, d, J = 7.0 Hz, 0.67H), 7.28 (major, t, J = 7.0 × 2 Hz, 
0.67H), 7.31-7.43 (ovlp m, 6H), 7.63 (minor, m, 0.33H), 8.31 (major, d, J = 14.1 Hz, 
0.67H); 8.70 (minor, br s, 0.33H), 11.03 (major, br s, 0.67H); 13C NMR (150 MHz, 
CDCl3) δ 28.08, 28.14, 54.0, 54.7, 83.4, 83.6, 108.4, 115.5, 115.6, 116.1, 116.3, 123.77, 
123.80, 124.68, 124.70, 127.7, 127.8, 128.51, 128.54, 128.64, 128.65, 128.77, 128.80, 
129.2, 129.3, 129.85, 129.88, 131.2, 131.3, 132.15, 132.20, 135.0, 135.2, 149.5, 150.3, 
157.5, 157.9, 158.25, 158.26, 159.2, 159.6, 161.9, 185.2, 188.8; 19F NMR (564 MHz, 
 48 
CDCl3) δ -120.1 (major), -117.4; HRMS (APCI–) calcd for C21H22FN2O5S– [M – H]– 
433.1239, found 433.1265 (error 6.0 ppm). 
tert-Butyl (1-benzyl-quinol-4-on-3-yl)sulfonylcarbamate (45) via tert-butyl (1-
(methoxymethyl)-quinol-4-on-3-yl)sulfonylcarbamate (49).39 To a stirred solution of Bn-
enaminone 49 (725 mg, 1.67 mmol, 1.00 equiv) in THF (7 mL) at 22 °C was added NaH 
(60% dispersion in mineral oil, 147 mg, 3.67 mmol, 2.20 equiv) portion-wise (~10 mg 
portions) such that noticeable gas evolution had ceased before next addition. After 
stirring 1 h, the reaction was quenched by addition of satd aq NH4Cl (25 mL). The 
aqueous mixture was acidified to pH ~4 (pH paper) with aq 6 N HCl and was then 
extracted with EtOAc (4 × 25 mL). The organic layers were combined, dried (MgSO4), 
and concentrated under reduced pressure yielding an off-white solid (436 mg). 
Purification by flash chromatography (0.4:0.4:39.2:60 to 1:10:89:0 
HCO2H/MeOH/EtOAc/hexanes gradient) afforded the title compound (351 mg, 51%) as 
an amorphous off-white solid: Characterization data match that as given above. 
N6,N6-Bis(tert-butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -(1-
benzyl-quinol-4-on-3-yl)sulfonyl- 2′,3′-O-isopropylideneadenosine (50). To a stirred 
solution of quinolone 45 (228 mg, 0.550 mmol, 1.10 equiv), bis-Boc isopropylidene 
adenosine 9 (254 mg, 0.500 mmol, 1.00 equiv), and PPh3 (144 mg, 0.550 mmol, 1.10 
equiv) in THF (50 mL) at 22 °C was added DIAD (108 µL, 0.550 mmol, 1.10) dropwise 
over 5 min. After stirring 1 h, the reaction was concentrated in vacuo yielding an off-
white foamy residue (816 mg). Purification by flash chromatography (40:60 
EtOAc/hexanes) afforded the title compound (385 mg, 85%) as an off-white foamy 
residue: Rf 0.27 (0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, 
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CDCl3) δ 1.32 (s, 9H), 1.41 (s, 18H), 1.47 (s, 3H), 1.66 (s, 3H), 4.34 (dd, J = 15.0, 6.2 
Hz, 1H), 4.46 (dd, J = 15.0, 6.2 Hz, 1H), 4.67 (td, J = 6.2 × 2, 3.5 Hz, 1H), 5.21 (dd, J = 
6.5, 3.5 Hz, 1H), 5.36 (dd, J = 6.5, 2.6 Hz, 1H), 5.43 (s, 2H), 6.25 (d, J = 2.6 Hz, 1H), 
7.19 (d, J = 7.0 Hz, 2H), 7.34 (ovlp m, 3H), 7.40 (d, J = 8.2 Hz, 1H), 7.45 (t, J = 8.2 × 2 
Hz, 1H), 7.61 (t, J = 7.0 × 2 Hz, 1H), 8.36 (s, 1H), 8.42 (d, J = 8.2 Hz, 1H), 8.61 (s, 1H), 
8.92 (s, 1H); 13C NMR (150 MHz, CDCl3) δ 25.7, 27.5, 27.9, 28.0, 49.5, 58.0, 82.4, 83.8, 
84.3, 84.6, 85.2, 90.6, 115.0, 117.2, 118.6, 126.0, 126.3, 127.5, 128.5, 129.0, 129.5, 
129.6, 133.6, 133.8, 139.4, 143.9, 149.4, 150.4, 150.6, 151.1, 152.4, 152.8, 172.2; HRMS 
(ESI+) calcd for C44H54N7O12S+ [M + H]+ 904.3546, found 904.3537 (error 1.0 ppm). 
N6,N6-Bis(tert-butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -
(quinol-4-on-3-yl)sulfonyl- 2′,3′-O-isopropylideneadenosine (51). To a Parr flask 
flushed with Ar was added Pd/C (10% by weight, 436 mg, 0.410 mmol, 1.00 equiv), a 
solution of N-benzyl quinolone-AMS 50 (371 mg, 0.410 mmol, 1.00 equiv) in anhydrous 
MeOH (10 mL), and AcOH (23 µL, 0.41 mmol, 1.0 equiv) respectively. The reaction 
vessel was evacuated, then backfilled with H2 to 40 psi, and the mixture was shaken at 22 
°C for 4 h. The reaction mixture was filtered through celite and concentrated to an off-
white amorphous solid (454 mg). Purification by flash chromatography (65:35 
EtOAc/hexanes) afforded the title compound (195 mg, 58%) as an off-white amorphous 
solid: Rf 0.54 (0.75:0.75:73.5:25 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, 
DMSO-d6) δ 1.12 (s, 9H), 1.35 (s, 18H), 1.37 (s, 3H), 1.57 (s, 3H), 4.09 (dd, J = 15.0, 7.6 
Hz, 1H), 4.14 (dd, J = 15.0, 6.8 Hz, 1H), 4.48 (ap td, J = 7.6, 6.8, 3.4 Hz, 1H), 5.24 (dd, J 
= 6.2, 3.4 Hz, 1H), 5.60 (dd, J = 6.2, 1.6 Hz, 1H), 6.40 (d, J = 1.6 Hz, 1H), 7.47 (t, J = 
8.2 × 2 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.77 (t, J = 8.2 × 2 Hz, 1H), 8.12 (d, J = 8.2 
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Hz, 1H), 8.30 (s, 1H), 8.58 (D2O-exchangeable [collapses to singlet], d, J = 6.2 Hz, 1H), 
8.81 (s, 1H), 8.88 (s, 1H), 12.79 (D2O-exchangeable, d, J = 6.2 Hz, 1H); 13C NMR (150 
MHz, 1:10 D2O/DMSO-d6) δ 25.5, 27.2, 27.6, 49.4, 79.3, 82.2, 83.8, 83.90, 83.93, 86.3, 
89.5, 113.9, 117.8, 119.5, 125.5, 126.1, 126.5, 128.6, 133.9, 139.2, 144.8, 146.0, 149.6, 
150.3, 150.8, 152.0, 152.8, 171.8; HRMS (ESI+) calcd for C37H48N7O12S+ [M + H]+ 
814.3076, found 814.3071 (error 0.6 ppm). 
5′-Amino-5′-N-[((quinol-4-on)-3-yl)sulfonyl]adenosine (2) via N6,N6-Bis(tert-
butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -(quinol-4-on-3-yl)sulfonyl- 
2′,3′-O-isopropylideneadenosine (51). To debenzyl quinolone-AMS 51 (97 mg, 0.12 
mmol, 1.0 equiv) at 0 °C was added ice-cold 80% aq TFA (2 mL). The reaction was 
stirred 19 h at 0 °C. The reaction was concentrated in vacuo and subsequent purification 
by flash chromatography (1:10:98 HCO2H/MeOH/EtOAc) afforded the title compound 
(40 mg, 70%) as a colorless amorphous solid. Further purification of a portion (4.3 mg) 
by RP-HPLC (12.5:87.5 MeCN/H2O) and lyophilization of appropriate fractions afforded 
the title compound (2 mg) as a fluffy colorless solid: Characterization data matched that 
as given above. 
Compounds from Figure 21 
tert-Butyl (2-(2-fluorophenyl)-1-(hydroxyimino)-2-oxoethyl)sulfonylcarbamate 
(52).47 To a solution of β-ketosulfonamide 34 (635 mg, 2.00 mmol, 1.00 equiv) in 
AcOH/H2O/THF (2.5 mL, 2.5 mL, 5.0 mL respectively) at 0 °C was added NaNO2 (276 
mg, 4.00 mmol, 2.00 equiv). After stirring 19 h, the reaction mixture was diluted with 
H2O (50 mL) and was extracted with EtOAc (3 × 50 mL). The combined organic layer 
was dried (MgSO4) and concentrated, yielding a light yellow oil. Purification by flash 
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chromatography (0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes) afforded the title 
compound (513 mg, 74%) as an off-white foamy residue: Rf 0.40 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CD3OD) δ 1.48 (s, 9H), 7.25 (dd, 
J = 10.6, 8.8 Hz, 1H), 7.36 (ap t, J = 7.6 Hz × 2, 1H), 7.71 (dddd, J = 8.8, 7.0, 5.3, 1.8 
Hz, 1H), 7.92 (td, J = 7.6 × 2, 1.8 Hz, 1H); 13C NMR (150 MHz, CD3OD) δ 28.2, 84.6, 
118.0 (d, 2JC-F = 22.0 Hz), 124.7 (d, 2JC-F = 8.1 Hz), 125.9 (d, 3JC-F = 3.5 Hz), 132.7, 
138.1 (d, 3JC-F = 9.2 Hz), 151.5, 155.3, 163.5 (d, 1JC-F = 261.3 Hz), 184.9; 19F NMR (564 
MHz, CDCl3) δ -115.3; HRMS (ESI–) calcd for C13H14FN2O6S– [M – H]– 345.0562, 
found 345.0569 (error 2.0 ppm). 
tert-Butyl (4-oxo-4H-benzo[e][1,2]oxazin-3-yl)sulfonylcarbamate (53).48 To a 
solution of oxime 52 (228 mg, 0.657 mmol, 1.00 equiv) in DMF (3.5 mL) at 22 °C was 
added Cs2CO3 (471 mg, 1.45 mmol, 2.20 equiv). After stirring 4.5 h the reaction mixture 
was quenched with satd aq NH4Cl (20 mL). The aqueous solution was acidified to pH ~4-
5 (pH paper) with aq 6 N HCl and was then extracted with EtOAc (3 × 30 mL). The 
organic layers were combined, dried (MgSO4), and concentrated under reduced pressure 
yielding a pale yellow residue. Purification by flash chromatography (0.2:0.2:19.6:80 
HCO2H/MeOH/EtOAc/hexanes) afforded the title compound (124 mg, 58%) as a pale 
yellow residue: Rf 0.57 (0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 
MHz, CDCl3) δ 1.42 (s, 9H), 7.54 (ap t, J = 7.9, 7.3 Hz, 1H), 7.62 (d, J = 8.2 Hz, 1H), 
7.90 (ap t, J = 8.2, 7.3 Hz, 1H), 8.15 (d, J = 7.9 Hz, 1H), 8.58 (br s, 1H); 13C NMR (150 
MHz, CDCl3) δ 27.8, 85.3, 116.9, 121.2, 125.4, 127.5, 137.3, 149.1, 156.2, 162.0, 163.6; 
HRMS (ESI–) calcd for C13H13N2O6S– [M – H]– 325.0500, found 325.0507 (error 2.2 
ppm). 
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N6,N6-Bis(tert-butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -(4-
oxo-4H-benzo[e][1,2]oxazin-3-yl)sulfonyl- 2′,3′-O-isopropylideneadenosine (54). To a 
solution of benzoxazine sulfonamide 53 (45.4 mg, 0.139 mmol, 1.10 equiv), bis-Boc 
isopropylidene adenosine 9 (64 mg, 0.13 mmol, 1.0 equiv), and PPh3 (36 mg, 0.14 mmol, 
1.1 equiv) in THF (5 mL) was added DIAD (27 µL, 0.14 mmol, 1.1 equiv). After 4 h 
stirring, LRMS monitoring of the reaction suggested limiting reagent 9 remained; more 
PPh3 (36 mg, 0.14 mmol, 1.1 equiv) and DIAD (27 µL, 0.14 mmol, 1.1 equiv) were 
added. After a further 19 h stirring, LRMS monitoring of the reaction suggested limiting 
reagent 9 still remained; more PPh3 (36 mg, 0.14 mmol, 1.1 equiv) and DIAD (27 µL, 
0.14 mmol, 1.1 equiv) were added. After a final 7.5 h stirring, LRMS monitoring 
suggested the total consumption of 9. The reaction was concentrated to an off-white 
residue. Purification by flash chromatography (30:70 EtOAc/hexanes) afforded the title 
compound (46 mg, 45%) as an off-white oily residue: Rf 0.53 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 1.32 (s, 9H), 1.40 (s, 
18H), 1.41 (s, 3H), 1.64 (s, 3H), 4.18 (dd, J = 14.7, 7.6 Hz, 1H), 4.25 (dd, J = 14.7, 5.3 
Hz, 1H), 4.69 (m, 1H), 5.23 (dd, J = 6.2, 2.9 Hz, 1H), 5.49 (dd, J = 5.9, 1.8 Hz, 1H), 6.22 
(d, J = 1.8 Hz, 1H), 7.53 (t, J = 7.9 × 2 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.88 (ap td, J = 
8.5, 7.9, 1.2 Hz, 1H), 8.11 (dd, J = 7.9, 1.2 Hz, 1H), 8.22 (s, 1H), 8.88 (s, 1H); 13C NMR 
(150 MHz, CDCl3) δ 25.6, 27.3, 27.89, 27.93, 49.5, 82.6, 83.8, 84.6, 85.8, 86.3, 91.0, 
114.8, 116.9, 121.2, 125.4, 127.4, 128.4, 129.7, 137.1, 144.3, 150.4, 150.6, 152.2, 152.7, 
157.1, 161.9, 163.3; HRMS (ESI+) calcd for C36H46N7O13S+ [M + H]+ 816.2869, found 
816.2851 (error 2.2 ppm). 
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5′-Amino-5′-N-[(4-oxo-4H-benzo[e][1,2]oxazin-3-yl)sulfonyl]adenosine (3). To 
Mitsunobu product 54 (47 mg, 0.058 mmol, 1.0 equiv) at 0 °C was added ice-cold 80% 
aq TFA (2 mL). The reaction was stirred 19 h at 0 °C. The reaction was concentrated in 
vacuo and subsequent purification by flash chromatography (1:1:98 
HCO2H/MeOH/EtOAc) afforded the title compound (22 mg, 81%) as a colorless 
amorphous solid. Further purification by RP-HPLC (17.5:82.5 MeCN/H2O) and 
lyophilization of appropriate fractions afforded the title compound (12 mg) as a fluffy 
colorless solid: Rf 0.32 (1:10:89 HCO2H/MeOH/EtOAc); 1H NMR (600 MHz, 1:10 
D2O/DMSO-d6) δ 3.42-3.46 (ovlp m, 2H), 4.03 (m, 1H), 4.07 (dd, J = 5.6, 2.9 Hz, 1H), 
4.58 (t, J = 6.2, 5.6 Hz, 1H), 5.67 (d, J = 6.2 Hz, 1H), 7.51 (dd, J = 8.2, 7.6 Hz, 1H), 7.53 
(d, J = 8.2 Hz, 1H), 7.86 (dd, J = 8.2, 7.6 Hz, 1H), 7.98 (d, J = 8.2 Hz, 1H), 8.12 (s, 1H), 
8.19 (s, 1H); 13C NMR (150 MHz, 1:10 D2O/DMSO-d6) δ 46.0, 71.2, 73.0, 84.0, 88.2, 
116.7, 119.5, 120.8, 124.8, 127.2, 137.2, 140.6, 148.9, 152.4, 156.0, 157.4, 161.4, 164.4; 
HRMS (ESI+) calcd for C18H18N7O7S+ [M + H]+ 476.0983, found 476.0996 (error 2.7 
ppm). 
Compounds from Figure 22 
Methyl 2,3-dihydroxybenzoate (55).49 To a solution of 2,3-dihydroxybenzoic acid 
(3.08 g, 20.0 mmol, 1.00 equiv) in methanol (20 mL) at 0 °C was added SOCl2 (1.6 mL, 
22 mmol, 1.1 equiv). The solution was heated at 80 °C. After 21 h, the solution was 
cooled to 22 °C and diluted with EtOAc (20 mL). The solution was then cooled to 0 °C 
and the acidity quenched by addition of satd aq NaHCO3 (20 mL). The layers were 
separated and more satd aq NaHCO3 added to the aqueous layer to increase its pH (~9-
10). The aqueous layer was subsequently extracted with EtOAc (3 × 20 mL). The 
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combined organic layer was dried (MgSO4) and concentrated, yielding a colorless 
amorphous solid. Purification by flash chromatography (0:100 to 1:99 MeOH/DCM 
gradient) afforded the title compound (3.02 g, 90%) as an off-white amorphous solid: Rf 
0.69 (0.25:0.25:24.5:75 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, DMSO-
d6) δ 3.88 (s, 3H), 6.74 (t, J = 7.9 × 2 Hz, 1H), 7.03 (dd, J = 7.9, 1.5 Hz, 1H), 7.23 (dd, J 
= 7.9, 1.5 Hz, 1H), 9.40 (s, 1H), 10.42 (s, 1H); 13C NMR (150 MHz, DMSO-d6) δ 52.4, 
113.0, 118.9, 119.6, 120.7, 146.1, 149.5, 169.9; HRMS (ESI–) calcd for C8H7O4– [M – 
H]– 167.0350, found 167.0342 (error 4.8 ppm). 
Methyl 2,3-bis((tert-butyldimethylsilyl)oxy)benzoate (56).54 To a solution of 
catechol 55 (2.95 g, 17.5 mmol, 1.00 equiv) in DMF (35 mL) was added imidazole (6.20 
g, 91.1 mmol, 5.20 equiv) and TBSCl (7.92 g, 52.6 mmol, 3.00 equiv). The solution was 
heated at 65 °C. After 19 h, the solution was cooled to ambient temperature and diluted 
with 5% aq NaHCO3 (100 mL), extracted with hexanes (3 × 100 mL), dried (MgSO4) and 
concentrated yielding a colorless oil (8.77 g). Purification by flash chromatography (2:98 
EtOAc/hexanes) afforded the title compound (6.93 g, 99%) as a colorless oil: Rf 0.37 
(0.025:0.025:2.45:97.5 HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, DMSO-d6) 
δ 0.03 (s, 6H), 0.22 (s, 6H), 0.94 (s, 9H), 0.95 (s, 9H), 3.76 (s, 3H), 6.93 (ap t/dd, J = 7.6, 
8.2 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H); 13C NMR (150 MHz, 
DMSO-d6) δ -4.4, -3.9, 17.9, 18.3, 25.7, 25.9, 51.8, 121.4, 122.9, 123.9, 125.3, 145.1, 
147.6, 166.7; HRMS (ESI+) calcd for C20H37O4Si2+ [M + H]+ 397. 2225, found 397.2226 
(error 0.3 ppm). 
tert-Butyl (2-(2,3-dihydroxyphenyl)-2-oxoethyl)sulfonylcarbamate (58).17 Freshly 
titrated n-BuLi (2.1 M in hexane, 11.0 mL, 23.2 mmol, 3.10 equiv) was added dropwise 
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to freshly distilled (i-Pr)2NH (3.5 mL, 24.8 mmol, 3.30 equiv) in THF (24 mL) at 0 °C. 
The mixture was stirred for 1.5 h, then sulfonamide 36 (1.46 g, 7.50 mmol, 1.00 equiv) in 
THF (24 mL) was added and the reaction stirred for a further 1.5 h at 0 °C. Next, methyl 
ester 56 (3.25 g, 8.20 mmol, 1.10 equiv) was added and the reaction was stirred for 1.5 h 
at 0 °C. The reaction mixture was quenched with satd aq NaCl (25 mL) and 0.5 M aq 
NaH2PO4 (25 mL) and was diluted with EtOAc (25 mL). The layers were separated and 
the aqueous layer acidified to pH ~3-4 (pH paper) with aq 6 N HCl. The aqueous was 
then extracted with EtOAc (3 × 100 mL). The organic layers were combined, dried 
(MgSO4), and concentrated under reduced pressure yielding a golden foamy residue (4.73 
g). The residue was dissolved in THF (24 mL) and cooled to 0 °C. TBAF (1.0 M in THF, 
18.0 mL, 18.0 mmol, 2.40 equiv) was added and the solution stirred at 0 °C for 1 h. The 
reaction mixture was quenched with satd aq NH4Cl (25 mL). The layers were separated 
and the aqueous layer acidified to pH ~3-4 (pH paper) with aq 6 N HCl. The aqueous was 
then extracted with EtOAc (3 × 40 mL). The organic layers were combined, dried 
(MgSO4), and concentrated under reduced pressure yielding a dark oily residue (7.25 g). 
Purification by flash chromatography (0.3:0.3:29.4:70 HCO2H/MeOH/EtOAc/hexanes) 
afforded the title compound (2.05 g, 82%) as a yellow solid: Rf 0.69 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, DMSO-d6) δ 1.43 (s, 9H), 5.16 (s, 
2H), 6.79 (ap t, J = 7.6, 8.2 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 
9.69 (br s, 1H), 10.70-11.90 (ovlp br s, 2H); 13C NMR (150 MHz, DMSO-d6) δ 27.8, 
59.7, 82.5, 119.1, 121.5, 121.6, 121.7, 146.3, 150.0, 150.7, 193.0; HRMS (ESI–) calcd 
for C13H16NO7S– [M – H]– 330.0653, found 330.0662 (error 2.7 ppm). 
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tert-Butyl (8-hydroxychromon-3-yl)sulfonylcarbamate (60).24,25 N,N-
Dimethylformamide dimethylacetal (638 µL, 4.80 mmol, 2.40 equiv) was added to a 
solution of β-ketosulfonamide 58 (663 mg, 2.00 mmol, 1.00 equiv) in THF (20 mL) at 22 
°C. The solution was stirred for 18 h, then was acidified with satd aq NH4Cl (25 mL) and 
diluted with EtOAc (25 mL). The layers were separated and the aqueous layer acidified 
to pH ~5-6 (pH paper) with aq 6 N HCl. The aqueous was then extracted with EtOAc (2 
× 25 mL). The organic layers were combined, dried (MgSO4), and concentrated under 
reduced pressure yielding a golden foamy residue. Purification by flash chromatography 
(0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes) afforded the title compound (536 mg, 
79%) as an off-white amorphous solid: Rf 0.48 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, DMSO-d6) δ 1.29 (s, 9H), 7.35 
(dd, J = 7.6, 1.2 Hz, 1H), 7.39 (t, J = 7.6 × 2 Hz, 1H), 7.52 (dd, J = 7.6, 1.2 Hz, 1H), 9.07 
(s, 1H), 10.91 (s, 1H), 11.94 (s, 1H); 13C NMR (150 MHz, DMSO-d6) δ 27.5, 82.2, 114.3, 
120.6, 122.8, 125.0, 127.0, 145.1, 147.2, 149.7 162.6, 170.7; HRMS (ESI–) calcd for 
C14H14NO7S– [M – H]– 340.0496, found 340.0529 (error 9.7 ppm). 
tert-Butyl (8-(methoxymethoxy)chromon-3-yl)sulfonylcarbamate (61).50 To a 
solution of hydroxy chromone 60 (465 mg, 1.36 mmol, 1.00 equiv) and DIPEA (0.30 mL, 
1.7 mmol, 1.3 equiv) in DMF (10 mL) at 0 °C was added MOMCl (124 µL, 1.63 mmol, 
1.20 equiv). The reaction was stirred 25 h and was diluted with DCM (100 mL). The 
solution was washed with H2O (2 × 100 mL) and saturated aq NaCl (100 mL). The 
organic layer was dried (MgSO4) and concentrated yielding a yellow-orange solid (480 
mg). Purification by flash chromatography (0.3:0.3:29.4:70 
HCO2H/MeOH/EtOAc/hexanes) afforded the title compound (166 mg, 32%) as an off-
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white amorphous solid: Rf 0.51 (0.5:0.5:49:50 HCO2H/MeOH/EtOAc/hexanes); 1H NMR 
(600 MHz, DMSO-d6) δ 1.30 (s, 9H), 3.35 (s, 3H), 5.22 (s, 2H), 7.37 (dd, J = 7.6, 1.2 Hz, 
1H), 7.40 (t, J = 7.6 × 2 Hz, 1H), 7.50 (dd, J = 7.6, 1.2 Hz, 1H), 9.21 (s, 1H), 10.99 (s, 
1H); 13C NMR (150 MHz, DMSO-d6) δ 27.3, 56.1, 78.8, 84.6, 114.2, 120.8, 123.2, 124.8, 
127.2, 145.2, 147.3, 150.0, 162.8, 171.0; HRMS (ESI–) calcd for C16H18NO8S– [M – H]– 
384.0759, found 384.0790 (error 8.1 ppm). 
N6,N6-Bis(tert-butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -((8-
(methoxymethoxy)chromon-3-yl)sulfonyl- 2′,3′-O-isopropylideneadenosine (62). To 
a solution of chromone sulfonamide 61 (42 mg, 0.11 mmol, 1.1 equiv), adenosine 9 (51 
mg, 0.10 mmol, 1.0 equiv), and PPh3 (29 mg, 0.11 mmol, 1.1 equiv) in THF (5 mL) at 22 
°C was added DIAD (22 µL, 0.11 mmol, 1.1 equiv). After 2 h stirring, TLC monitoring 
of the reaction suggested limiting reagent 9 remained; more PPh3 (29 mg, 0.11 mmol, 1.1 
equiv) and DIAD (22 µL, 0.11 mmol, 1.1 equiv) were added. After another 2.5 h stirring, 
the reaction appeared complete by TLC. The reaction mixture was concentrated to an off-
white residue. Purification by flash chromatography (40:60 EtOAc/hexanes) afforded the 
title compound (24.4 mg, 28%) as an off-white amorphous solid: Rf 0.40 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 1.25 (s, 3H), 1.41 (s, 
9H), 1.47 (s, 18H), 1.68 (s, 3H), 3.51 (s, 3H), 4.34 (br s, 1H), 4.46 (br s, 1H), 4.76 (br s, 
1H), 5.27 (br s, 1H), 5.38 (s, 2H), 5.45 (br s, 1H), 6.31 (br s, 1H), 7.18 (br s, 1H), 7.37 (br 
s, 1H), 7.77 (br d, J = 6.5 Hz, 1H), 8.28 (br s, 1H), 8.79 (s, 1H), 8.87 (s, 1H); 13C NMR 
(150 MHz, CDCl3) δ 25.6, 27.4, 28.0, 28.1, 49.5, 57.0, 77.5, 78.2, 79.9, 81.6, 84.2, 85.2, 
91.0, 115.2, 117.4, 117.8, 124.8, 125.8, 126.9, 130.9, 134.9, 146.5, 147.8, 150.6, 150.7, 
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151.0, 152.4, 152.5, 161.6, 171.4; HRMS (ESI+) calcd for C39H51N6O15S+ [M + H]+ 
875.3128, found 875.3136 (error 0.9 ppm). 
5′-Amino-5′-N-[(8-hydroxychromon-3-yl)sulfonyl]adenosine (4). To Mitsunobu 
product 62 (24 mg, 0.027 mmol, 1.0 equiv) at 0 °C was added ice-cold 80% aq TFA (2.5 
mL). The reaction was stirred 18 h at 0 °C. The reaction was concentrated in vacuo and 
subsequent purification by flash chromatography (1:1:98 to 1:4:95 
HCO2H/MeOH/EtOAc gradient) afforded the title compound (8.9 mg, 66%) as a 
colorless amorphous solid. Further purification by RP-HPLC (12.5:87.5 MeCN/H2O) and 
lyophilization of appropriate fractions afforded the title compound (7.7 mg) as a fluffy 
colorless solid: Rf 0.22 (1:20:79 HCO2H/MeOH/EtOAc); 1H NMR (600 MHz, DMSO-d6) 
δ 4.33 (td, J = 5.3 × 2, 2.9 Hz, 1H), 4.41 (q, J = 5.3 × 3 Hz, 1H), 4.45 (dd, J = 11.2, 5.3 
Hz, 1H), 4.49 (dd, J = 11.2, 2.9 Hz, 1H), 4.75 (q, J = 5.3 × 3 Hz, 1H), 5.44 (D2O-
exchangeable, d, J = 5.3 Hz, 1H), 5.63 (D2O-exchangeable, d, J = 5.3 Hz, 1H), 6.01 (d, J 
= 5.3 Hz, 1H), 7.27 (D2O-exchangeable, br s, 2H), 7.38 (D2O-exchangeable, br s, 2H), 
7.49 (t, J = 7.6 × 2 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.67 (d, J = 7.6 Hz, 1H), 8.15 (s, 
1H), 8.38 (s, 1H), 8.97 (s, 1H); 13C NMR (150 MHz, DMSO-d6) δ 69.2, 70.4, 73.3, 82.0, 
87.5, 115.9, 117.4, 124.9, 126.5, 127.4, 132.7, 145.9, 147.7, 149.5, 152.7, 156.0, 158.0, 
171.2, 171.6; HRMS (ESI+) calcd for C19H19N6O8S+ [M + H]+ 491.0980, found 491.0995 
(error 3.1 ppm). 
Methyl 2-((tert-butyldimethylsilyl)oxy)benzoate (63).55 TBSCl (3.01 g, 20.0 mmol, 
3.00 equiv) was added to a solution of methyl salicylate (862 µL, 6.65 mmol, 1.00 equiv), 
imidazole (1.81 g, 26.6 mmol, 4.00 equiv), and DMAP (8 mg, 0.07 mmol, 0.01 equiv) in 
DMF (10 mL) at 0 °C. After stirring 1 h, the homogeneous solution had become a thick 
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suspension. The ice bath was removed and the reaction stirred a further 21.5 h. 5% aq 
NaHCO3 (100 mL) was added to the reaction and the resulting aqueous solution was 
extracted with Et2O (3 × 100 mL). The combined organic layers were dried (MgSO4) and 
concentrated yielding a colorless oil which was purified by flash chromatography (1:99 to 
10:90 Et2O/hexanes) yielding the title compound (1.41 g, 79%) as a colorless oil: Rf 0.19 
(1:99 EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 0.21 (s, 6H), 1.01 (s, 9H), 3.86 (s, 
3H), 6.87 (dd, J = 8.2, 1.2 Hz, 1H), 6.98 (ddd, J = 7.6 × 2, 1.2 Hz, 1H), 7.35 (ddd, J = 
8.2, 7.6, 1.8 Hz, 1H), 7.75 (dd, J = 7.6, 1.8 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ -4.2, 
18.4, 25.8, 52.0, 121.0, 121.3, 123.0, 131.7, 133.1, 155.2, 167.5; HRMS (ESI+) calcd for 
C14H23O3Si+ [M + H]+ 267.1411, found 267.1424 (error 4.9 ppm). 
tert-Butyl (2-(2-hydroxyphenyl)-2-oxoethyl)sulfonylcarbamate (65).17 Freshly 
titrated n-BuLi (2.1 M in hexane, 5.0 mL, 11 mmol, 3.1 equiv) was added dropwise to 
freshly distilled (i-Pr)2NH (1.6 mL, 11 mmol, 3.3 equiv) in THF (10 mL) at 0 °C. The 
mixture was stirred for 30 min, then sulfonamide 36 (666 mg, 3.41 mmol, 1.00 equiv) in 
THF (10 mL) was added and the reaction stirred for a further 1 h at 0 °C. Next, methyl 
ester 63 (1.00 g, 3.75 mmol, 1.10 equiv) in THF (2 mL) was added and the reaction was 
stirred for 3 d at 0 °C. The reaction mixture was quenched with satd aq NaCl (10 mL) and 
0.5 M aq NaH2PO4 (10 mL) and was diluted with EtOAc (10 mL). The layers were 
separated and the aqueous layer acidified to pH ~5-6 (pH paper) with 6 N aq HCl. The 
aqueous was then extracted with EtOAc (2 × 100 mL). The organic layers were 
combined, dried (MgSO4), and concentrated under reduced pressure yielding a golden 
oily residue (2.19 g). The residue was dissolved in THF (10 mL) and cooled to 0 °C. 
TBAF (1.0 M in THF, 8.2 mL, 8.2 mmol, 2.4 equiv) was added and the solution stirred at 
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0 °C for 17 h. The reaction mixture was quenched with satd aq NH4Cl (25 mL) and was 
diluted with Et2O (25 mL). The layers were separated and the aqueous layer acidified to 
pH ~5-6 (pH paper) with 6 N aq HCl. The aqueous was then extracted with Et2O (25 mL) 
and EtOAc (50 mL). The organic layers were combined, dried (MgSO4), and 
concentrated under reduced pressure yielding a golden oil (2.40 g). Purification by flash 
chromatography (0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes) afforded the title 
compound (930 mg, 86%) as an off-white solid: Rf 0.83 (0.5:0.5:49:50 
HCO2H/MeOH/EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 1.53 (s, 9H), 4.99 (s, 
2H), 6.98 (dd, J = 8.2, 7.6 Hz, 1H), 7.03 (d, J = 8.2 Hz, 1H), 7.57 (dd, J = 8.2, 7.6 Hz, 
1H), 7.76 (d, J = 8.2 Hz, 1H), 11.67 (s, 1H); 13C NMR (150 MHz, CDCl3) δ 28.1, 57.9, 
85.3, 119.0, 119.1, 119.9, 131.1, 138.4, 149.5, 163.5, 193.2; HRMS (APCI–) calcd for 
C13H16NO6S– [M – H]– 314.0704, found 314.0732 (error 8.9 ppm). 
tert-Butyl (chromon-3-yl)sulfonylcarbamate (8) via tert-butyl (2-(2-
hydroxyphenyl)-2-oxoethyl)sulfonylcarbamate (65).24,25 N,N-Dimethylformamide 
dimethylacetal (638 µL, 4.80 mmol, 2.40 equiv) was added to a solution of β-
ketosulfonamide 65 (631 mg, 2.00 mmol, 1.00 equiv) in THF (20 mL) at 22 °C. The 
solution was stirred for 18 h, then was acidified with satd aq NH4Cl (25 mL) and diluted 
with EtOAc (25 mL). The layers were separated and the aqueous layer acidified to pH 
~2-3 (pH paper) with aq 6 N HCl. The aqueous was then extracted with EtOAc (2 × 25 
mL). The organic layers were combined, dried (MgSO4), and concentrated under reduced 
pressure yielding a golden foamy residue. Purification by flash chromatography 
(0.2:0.2:19.6:80 HCO2H/MeOH/EtOAc/hexanes) afforded the title compound (484 mg, 
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74%) as an off-white amorphous solid: Characterization data matched that as given 
above. 
N6,N6-Bis(tert-butoxycarbonyl)-5′-amino-5′-N-(tert-butoxycarbonyl)- 5′-N -
(chromon-3-yl)sulfonyl- 2′,3′-O-isopropylideneadenosine (10) via β-ketosulfonamide 
65. To a stirred solution of Boc-protected chromone sulfonamide 8 (36 mg, 0.11 mmol, 
1.1 equiv), bis-Boc adenosine 9 (51 mg, 0.10 mmol, 1.0 equiv) and PPh3 (29 mg, 0.11 
mmol, 1.1 equiv) in THF (5 mL) at 0 °C was added DIAD (22 µL, 0.11 mmol, 1.1 equiv) 
in four portions over 5 min. The reaction was stirred 30 min at 0 °C and was then allowed 
to warm to 22 °C. TLC monitoring showed remaining adenosine after 4.5 h, so more 
PPh3 (29 mg, 0.11 mmol, 1.1 equiv) and DIAD (22 µL, 0.11 mmol, 1.1 equiv) were 
added. The reaction was stirred a further 4 h. TLC monitoring showed remaining 
adenosine, so more PPh3 (29 mg, 0.11 mmol, 1.1 equiv) and DIAD (22 µL, 0.11 mmol, 
1.1 equiv) were added. The reaction was stirred 17.5 hours overnight. TLC monitoring 
showed remaining adenosine, so more PPh3 (29 mg, 0.11 mmol, 1.1 equiv) and DIAD 
(22 µL, 0.11 mmol, 1.1 equiv) were added. The reaction was stirred another 4 h then was 
concentrated in vacuo. Purification by flash chromatography (40:60 EtOAc/hexanes) 
afforded the title compound (59 mg, 73%) as a colorless oil: Characterization data 
matched that as given above. 
5′-Amino-5′-N-[(chromon-3-yl)sulfonyl]adenosine (1) via β-ketosulfonamide 65. To 
Mitsunobu product 10 (54 mg, 0.066 mmol, 1.0 equiv) at 0 °C was added ice-cold 80% 
aq TFA (2.5 mL). The reaction was stirred 17 h at 0 °C. The reaction was concentrated in 
vacuo and subsequent purification by flash chromatography (1:1:98 to 1:3:96 
HCO2H/MeOH/EtOAc gradient) afforded the title compound (18 mg, 59%) as a colorless 
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amorphous solid. Further purification by RP-HPLC (15:85 MeCN/H2O) and 
lyophilization of appropriate fractions afforded the title compound (12 mg) as a fluffy 
colorless solid: Characterization data matched that as given above. 
Biochemical Evaluation. 
Cloning, Overexpression, and Purification of MbtA. Cloning of the mbtA gene, 
creation of plasmid pCDD003, and electroporation of pCDD003 into E. coli BL21(DE3) 
containing the groEL groES chaperone plasmid pGRO7 (Takara) has been previously 
described.18 Representative procedure for overexpression and purification, performed 
with the assistance of Daniel J. Wilson: Glycerol stocks of the aforementioned E. coli 
were plated on LB media supplemented with kanamycin (50 µg/mL) and 
chloramphenicol (25 µg/mL) and were incubated at 37 °C overnight. LB (2 × 5 mL) 
supplemented with kanamycin (50 µg/mL) and chloramphenicol (25 µg/mL) was 
inoculated with above colonies and was incubated with shaking at 37 °C overnight. LB (1 
L) supplemented with kanamycin (50 µg/mL), chloramphenicol (25 µg/mL), MgCl2 (10 
mM), and arabinose (0.5 mg/mL) was inoculated with the 10 mL of overnight culture and 
was incubated with shaking at 37 °C to an OD600 of 0.67. The culture was induced with 
0.4 mM IPTG and grown for an additional 3 h at 30 °C. The cultures were then 
centrifuged for 10 min at 5000 × g and 4 °C and resultant pellets frozen at -20 °C 
overnight. The pellets were resuspended in 22.5 mL GroEL stripping buffer A (100 mM 
Bicine, 170 mM NaCl, pH 7.6) and sonicated (Branson Sonifier 250, output 8, 30% for 4 
× 2 min). The lysate was centrifuged for 10 min at 45000 × g and 4 °C. Subsequently, 2.5 
mL GroEL stripping buffer B (100 mM Bicine, 200 mM MgCl2, pH 7.6) and 138 mg 
ATP were added to the supernatant and the pH was adjusted from ~5.5 to 7.6 with 1 N 
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NaOH. The lysate was incubated for 30 min at 4 °C. To ensure removal of GroEL, 140 
µL of denatured E. coli proteins prepared as previously described56 was added and the 
lysate was allowed to incubate for another 1 h at 4 °C. 2 mL of 50% Ni–NTA (Qiagen) 
was added to the lysate and it was incubated on an end-over-end mixer for 1 h at 4 °C. 
The lysate/Ni–NTA mixture was poured into a column and the flow through collected. 
The column was washed with 14 mL wash buffer (50 mM HEPES, 300 mM NaCl, 20 
mM imidazole, pH 8.0) and MbtA was then eluted with 3 mL of elution buffer (50 mM 
HEPES, 300 mM NaCl, 250 mM imidazole, pH 8.0) of which the first 0.5 mL (half of the 
dead volume) was discarded and the final 2.5 mL was collected. The MbtA solution was 
desalted on a PD-10 column (GE Healthcare) into MbtA storage buffer (10 mM 
Tris•HCl, 1 mM EDTA, 5% glycerol, pH 8.0) and stored overnight at -80 °C. To the 3.4 
mL solution of MbtA-SUMO in storage buffer was added 21 mg Tris•HCl to increase its 
concentration from 10 to 50 mM, 30 mg NaCl resulting in a concentration of 150 mM, 
1.5 mg MgCl2 to suppress the effects of 1 mM EDTA, and 680 µL 1% Igepal CA-630 
(Sigma) resulting in a final concentration of 0.2%. The solution’s pH was adjusted to 8.0. 
SUMO protease57 was added to make the solution 0.01 µM protease for each 1 µM 
MbtA-SUMO. The reaction was incubated for 15 h at 4 °C. After digestion, 0.5 mL of 
50% Ni–NTA was added to the sample to remove the SUMO tag, SUMO protease, and 
other E. coli proteins carried through purification. The mixture was incubated for 1 h at 4 
°C on an end-over-end mixer. The mixture was poured into a column and the flow 
through was collected. The resin was washed with SUMO buffer (50 mM Tris•HCl, 0.2% 
Igepal CA-630, 150 mM NaCl) and fractions containing MbtA were pooled. The protein 
was desalted on a PD-10 column into MbtA storage buffer. The protein concentration 
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was measured by the Bradford Assay (Bio-Rad) as 4.1 µM. The enzyme was stored at -80 
°C. 
Cloning, Overexpression, and Purification of BasE, EntE, and VibE. The cloning, 
overexpression, and purification of BasE,51 EntE,51,58 and VibE51,59 was performed by 
Daniel J. Wilson and has been previously described. 
Fluorescence Polarization Assays. Some of these assays were performed by Daniel J. 
Wilson using a modification of our previously described protocol.51 Briefly, FP 
measurements were performed on a Molecular Devices SpectraMax M5e with excitation 
and emission wavelengths of 485 and 530 nm, respectively, using PMT sensitivity set to 
high and 100 readings per well. Assays were performed in triplicate in flat bottom, black 
polystyrene 384-well plates (3575 Corning Inc.) in a final volume of 50 µL. To determine 
the equilibrium dissociation constant KD1 of our fluorescent probe Fl-Sal-AMS, a direct 
binding experiment in which the probe was titrated with enzyme was performed. 
Specifically, a three-fold serial dilution of enzyme (10 µL, from ~0.1-1000 nM MbtA and 
EntE and ~2-2000 nM BasE and VibE final concentrations) was added to a 40 µL 
solution of Fl-Sal-AMS (20 nM final concentration), FP buffer (30 mM Tris•HCl [pH 
7.5], 1 mM MgCl2, 0.0025% Igepal CA-630, and 1 mM final concentrations), and water. 
The fluorescence anisotropy was measured after a 30 min incubation at 22 °C. 
Experimentally measured anisotropies AOBS were fit to Equations 1 and 2 (below) using 
Mathmatica 8 (Wolfram Research Inc.) to give the KD1. To determine the equilibrium 
dissociation constant KD2 of each compound, a competitive binding experiment in which 
each was titrated into Fl-Sal-AMS and enzyme was performed. Specifically, a three-fold 
serial dilution of each compound (0.5 µL, ~1-100000 nM final concentrations) was added 
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to a 49.5 µL solution of Fl-Sal-AMS (20 nM final concentration), enzyme (50 nM MbtA 
and 200 nM BasE, EntE, and VibE final concentrations), FP buffer, and water. The 
fluorescence anisotropy was measured after a 30 min incubation at 22 °C. Displacement 
curves of measured fluorescent anisotropies versus varied compound concentrations were 
fit to Equations 1 and 3 to give the KD2. 
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[32P]PPi-ATP Exchange Assay. This assay was performed by Daniel J. Wilson as 
previously described.18 Briefly, reactions were performed under initial velocity 
conditions in a total volume of 101 µL. The reaction was set up in a volume of 90 µL and 
contained 250 µM salicylic acid (SAL), 10 mM ATP, 1 mM PPi, and 7 nM MbtA in 
assay buffer (75 mM Tris•HCl [pH 7.5], 10 mM MgCl2, 2 mM DTT). The inhibitors (1 
µL) in DMSO or DMSO only as a control were added. The reaction components were 
allowed to equilibrate for 10 min at 22 °C. Reactions were initiated by the addition of 10 
µL (0.5 µCi 32PPi, Perkin-Elmer 84.12Ci/mmol) in 50 mM sodium phosphate buffer (pH 
 66 
7.8) and placed at 37 °C for 20 min. Reactions were quenched by the addition of 200 µL 
quenching buffer (350 mM HClO4, 100 mM PPi, 1.8% w/v activated charcoal). The 
charcoal was pelleted by centrifugation and washed once with 500 µL water. The washed 
pellet was resuspended in 200 µL water, transferred to a scintillation vial, mixed with 15 
mL scintillation fluid (RPI), and counted on a Beckman LS6500. The counts from the 
bound γ-[32P]-ATP were directly proportional to initial velocity of the reaction and the 
data were fit to Morrison’s quadratic equation (Equation 4 below) for fitting 
concentration–response data for tight binding inhibitors as described by Copeland.60 
(4) 
  
€ 
vi
v0
= 1−
[E]T +[ I ]T + K i
app( )− ([E]T +[ I ]T + K iapp )2 − 4[E]T[ I ]T
2[E]T
 
Antitubercular Evaluation. 
M. tuberculosis H37Rv MIC Assay. This assay was performed by Helena I. Boshoff 
as previously described.14 Briefly, MICs were determined in quadruplicate in iron-
deficient GAST according to the broth microdilution method5 using drugs from DMSO 
stock solutions or with control wells treated with an equivalent amount of DMSO. All 
measurements reported herein used an initial cell density of 104–105 cells/assay, and 
growth was monitored at 10 and at 14 days, with the untreated and DMSO-treated control 
cultures reaching an OD620 ~0.2–0.3. Plates were incubated at 37 °C (100 µL/well) and 
growth was recorded by measurement of optical density at 620 nm. 
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